Validation of a general model for Intensity Modulated Radiation Therapy and Volumetric Modulated Arc Therapy quality assurance using an electronic portal imaging device. by Tyler, Madelaine Keenan
University of Wollongong 
Research Online 
University of Wollongong Thesis Collection 
1954-2016 University of Wollongong Thesis Collections 
2013 
Validation of a general model for Intensity Modulated Radiation Therapy 
and Volumetric Modulated Arc Therapy quality assurance using an 
electronic portal imaging device. 
Madelaine Keenan Tyler 
University of Wollongong Follow this and additional works at: https://ro.uow.edu.au/theses 
University of Wollongong 
Copyright Warning 
You may print or download ONE copy of this document for the purpose of your own research or study. The University 
does not authorise you to copy, communicate or otherwise make available electronically to any other person any 
copyright material contained on this site. 
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, 
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe 
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court 
may impose penalties and award damages in relation to offences and infringements relating to copyright material. 
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the 
conversion of material into digital or electronic form. 
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily 
represent the views of the University of Wollongong. 
Recommended Citation 
Tyler, Madelaine Keenan, Validation of a general model for Intensity Modulated Radiation Therapy and 
Volumetric Modulated Arc Therapy quality assurance using an electronic portal imaging device., Master 
of Science - Research thesis, Department of Engineering, University of Wollongong, 2013. 
https://ro.uow.edu.au/theses/3917 
Research Online is the open access institutional repository for the University of Wollongong. For further information 










Validation of a general model for Intensity Modulated Radiation 
Therapy and Volumetric Modulated Arc Therapy quality assurance 












"This thesis is presented as part of the requirements for the  
award of the Degree of Master of Science - Research 
of the 














I, Madelaine Tyler, declare that this thesis, submitted in partial fulfilment of the 
requirements for the award of Master of Science by Research, in the faculty of 
Engineering, University of Wollongong, is wholly my own work unless otherwise 
referenced or acknowledged. The document has not been submitted for qualifications 
at any other academic institution. 





















In this study, a simple method of performing treatment dose verification for Intensity 
Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy 
(VMAT) using an Electronic Portal Imaging Device (EPID) was investigated. This 
work was based on a model for IMRT verification using Varian EPIDs presented by 
Lee et al. (2009). The method presented by Lee et al. (2009) was modified and 
extended upon to include equipment from different vendors, different treatment 
planning systems, and to include verification of VMAT.  
The EPID dose verification QA system was designed and tested using an Elekta 
AxesseTM LINAC with an iViewGTTM EPID (Elekta AB, Sweden), and a Siemens 
Oncor ImpressionTM LINAC with an OptiVue 1000STTM EPID panel (Siemens 
Medical Solutions USA, Inc, USA).  
 
The EPID dose verification system compared flood field (FF) corrected EPID images 
(calibrated to absolute dose) and dose fluences generated by a treatment planning 
system (TPS) at a pre-determined depth in water (dref). The depth in water was 
determined as the depth in water that had closest agreement to the dose response 
properties of the EPID. Methods to determine dref are described and validation of the 
dosimetry system have been made with Step and Shoot IMRT and dynamic VMAT 
fields for 6 and 10 MV beam energies. Two different planning systems were used for 
patient field generation for comparison with the measured EPID fluences, XiO® 
v4.64 and Monaco® v3.10 (Elekta AB, Stockholm, Sweden).  
 
All measured IMRT and VMAT patient fields achieved greater than 95% agreement 
with the planning fluences (using 3 cGy / 3 mm gamma criteria) and were 
comparable to the pass-rates obtained by using the MapCHECK® two-dimensional 
diode array (Sun Nuclear Corporation, Florida, USA) as per current department 
procedure for IMRT dose verification. The dosimetry system developed using the 
EPID was found to be a suitable tool for use in clinical pre-treatment dose 
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1.1 PROJECT AIMS 
Accurate and efficient pre-treatment dose verification of Intensity Modulated 
Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) is 
required in radiotherapy cancer treatment (ICRU Report 83 2010). An increase in 
utilisation of complex treatment techniques such as IMRT and VMAT which require 
individual patient pre-treatment dose verification has increased the workload of 
radiotherapy departments due to equipment, time and financial considerations 
associated with IMRT and VMAT treatment and per-patient quality assurance (QA). 
Finite resources available in most departments necessitate that an IMRT / VMAT 
dosimetry system must be cost-effective, efficient, and accurate to ensure the 
implementation of an IMRT / VMAT program is practical. In a department where 
multiple machines are capable of IMRT / VMAT deliveries, pre-treatment dose 
verification QA scheduled at the same time on multiple machines produces strain on 
equipment and staff resources. 
 
Electronic Portal Imaging Devices (EPIDs) are a standard accessory with all modern 
Linear Accelerators (LINACs) for patient positioning and verification prior to 
radiotherapy treatment (Image-Guided Radiation Therapy (IGRT)) (Kirby and 
Glendinning 2006). The use of EPIDs for dose verification has been demonstrated 
using a variety of techniques with a comprehensive review presented by Van Elmpt 
et al. (2008). Most of the reported methods for EPID dosimetry require specialised 
skills that are not widely available, limiting the widespread implementation of EPID 
dosimetry. This project focused on a simple method for the quantification of absolute 
dose obtained from images acquired with EPIDs, and the subsequent development 
and implementation of a vendor-independent model for patient-specific dose 
verification of IMRT and VMAT treatment plans. 
 
The specific aims of this project were to: 
i. Determine the dosimetric properties of EPIDs in megavoltage radiation 




with dose, and field size dependence of flood field (FF) corrected images 
from a Siemens OptiVue 1000STTM and Elekta iViewGTTM EPID.  
ii. Determine a reference depth in water, dref where the dose response of each 
EPID detector panel closely corresponds to the dose response of reference 
dosimeters in water.  
iii. Calibrate EPID pixel values to dose at the corresponding dref, then compare 
dose profiles measured using calibrated EPIDs for open fields, and highly-
modulated test patterns, to the dose profiles generated by a treatment 
planning system (TPS) at dref for these fields.  
iv. Develop and evaluate this technique as a method for patient-specific dose 
verification QA of IMRT and VMAT plans using any combination of EPID, 
TPS, beam energy and delivery technique. Demonstrate the feasibility of this 
method for routine clinical IMRT and VMAT QA. 
 
1.2 CANCER 
Cancer describes a disease in which some normal cells of the body become 
genetically mutated and, without undergoing cellular death, can continue to multiply 
out of control in this mutated state thus causing the formation of a tumour. These 
mutated cells can be confined to a single site in the body within a single tumour 
(primary tumour) or travel to other sites in the body and continue to proliferate 
(metastases) (AIHW 2010).   
 
The latest report from the Australian Institute of Health and Welfare (AIHW) on the 
incidence of cancer in Australia was published in 2010 and estimated that in 2010 
there would be a total of 539 800 people with various forms of the disease, which 
was based on the 2007 diagnosis rate of 108 368 new cases. Cancer accounted for a 
total of 19% of the total burden of disease for the population at the time of the 
publication (AIHW 2010). 
 
1.3 CANCER TREATMENT 
Three principle techniques are used for the management of malignant disease; 




following treatment is dependent on the tumour type, site and staging. Often a patient 
will undergo a treatment regime using a combination of techniques to improve 
tumour control and outcome (Wang 2000). 
 
1.3.1 Surgery 
The goal of radical surgery for tumour removal is to extract the gross palpable 
tumour and any microscopic extensions of the disease. The microscopic extensions 
are difficult to detect and to extract surgically. As a result the gross tumour volume is 
sometimes removed by surgery with the suspected microscopic extensions targeted 
with radiotherapy (Wang 2000). 
 
1.3.2 Chemotherapy 
Chemotherapy is the application of chemically toxic drugs into the body that target 
tumour cells to achieve cell kill. The chemotherapeutic drugs act on fast-proliferating 
(rapidly dividing) cells to impair mitotic function. Chemotherapy is administered on 
a regimented cycle to optimise the kill of the targeted cells whilst minimising kill to 
the non-targeted cells (Airley 2009). Chemotherapy is a systemic treatment that is 
often combined with localised therapies such as surgery and/or radiotherapy in the 
treatment of cancer, where surgery or radiotherapy targets the local disease and 
chemotherapy targets microscopic spread of the disease. 
 
1.3.3 External Beam Radiation Therapy 
Radiation therapy involves the use of ionising radiation to cause irreversible damage 
to the tumour cells inducing cell death. The goal of radiotherapy is to target the 
tumour volume whilst sparing the surrounding normal healthy tissue by optimising 
beam shapes and angles (Webb 2003).  
 
External beam radiation therapy (EBRT) uses a radiation beam incident externally on 
the patient to treat an internal tumour volume. This is achieved through the use of a 




For the purpose of this Masters thesis EBRT will be discussed in terms of LINAC 
generated x-ray beams. 
 
EBRT consists of three phases: image acquisition, planning and treatment. Image 
acquisition is performed using modern imaging equipment such as Computed 
Tomography (CT) scanners, Magnetic Resonance Imagers (MRI) and, more recently, 
Positron Emission Tomography (PET) imagers. These imaging modalities allow the 
reconstruction of patient data into a 3-D data set for planning purposes. For accurate 
localisation of disease and radiotherapy treatment planning, registration of different 
imaging modalities is required where CT images are the reference data set since it 
provides accurate spatial and radiological information of the patient. Image 
registration is the correlation of two or more data sets to identify and match 
corresponding structures (Khan 2010). Registration techniques using CT data with 
MRI (which provides higher soft tissue contrast) allows more accurate tumour 
delineation in regions such as the brain, and CT with PET (providing functional 
information) allows accurate delineation of the active tumour volume extent. The 
patient is scanned in the treatment position for reproducibility and accuracy of 
planning (Meyer 2007). In radiotherapy, image registration can be rigid (where one 
image data set is overlaid on another and shifted to provide the best match of 
anatomy) or deformable where one image data set is  manipulated / deformed to 
match that of the reference data set. The most common deformable registration 
method is that of the Demon’s method which is detailed by Wang et al. (2005).  
 
The patient imaging data set is transferred to the Radiotherapy Treatment Planning 
System (TPS). The TPS contains beam models of the individual LINACs in the 
department. The model based data used for treatment planning is matched to 
experimentally collected beam data during LINAC commissioning measurements.  
The model based methods are able to calculate planned dose during a virtual 
treatment to the patient image set using the beam data. The radiation oncologist 
defines the target volume and prescribes the treatment, including dose levels to the 
target and dose limits to critical structures. The radiation therapist develops a 




for treatment, it is exported to the Record and Verify (R&V) system and eventually 
to the LINAC for treatment (Khan 2010). 
 
Treatment is performed in the position used for image acquisition. The patient is set 
up on the treatment couch and aligned with the external lasers to the planned 
isocentre (from the TPS coordinates). Prior to treatment the patient’s position can be 
verified using a variety of available imaging technologies (Jaffray et al. 2007). For 
example megavoltage (MV) EPIDs or kilovoltage (kV) cone beam CT (kV CBCT) 
may be acquired and registered to reference images to align the patient to the planned 
position. Alignment is performed using matches between anatomy (bony anatomy or 
fiducial markers) or using the field edges between the portal images acquired at the 
time of treatment and the planning digital reconstructed radiographs (DRRs) 
produced by the TPS. Once the position is verified, the patient is treated in small 
fractions over several weeks to achieve the total dose required for tumour kill. Small 
fractions (~2 Gy) with daily breaks are used due to the specific radiobiology of the 
tumour cells (Wigg 2001). 
 
1.4 RADIATION THERAPY TREATMENT METHODS 
1.4.1 3D Conformal Radiation Therapy 
3D conformal radiation therapy (3DCRT) was implemented in radiotherapy 
following the introduction of the CT scanner in 1972 (Webb 2001(b)). The CT 
scanner can be used to acquire a 3D tomographic volume of the patient anatomy in 
the specified area to be imaged.  
 
The reconstructed CT scan was imported into the TPS where the target (tumour) and 
any organs at risk were able to be delineated by the radiation oncologist on each of 
the acquired 2D CT slices, forming a reconstructed 3D patient volume. Beam 
arrangements and shapes were then optimised as a result of the virtual simulation on 
the 3D volume, allowing a more conformal treatment and target coverage than 





3DCRT can be used for all treatment sites in radiotherapy, however with improved 
3D imaging and contouring, the complexity of target volumes and organs at risk 
surrounding the volumes demanded a more conformal technique. 
 
 
Figure 1.4.1: Comparison of radiotherapy treatment delivery techniques from 2-D, 
to 3D-CRT to Intensity Modulated Radiation Therapy (clockwise from top left) 
(Webb 2003). 
 
1.4.2 Intensity Modulated Radiation Therapy  
IMRT is a highly conformal radiation therapy technique using Multi-Leaf 
Collimators (MLCs) to modulate the dose of radiation within each treatment field, 
optimising the composite dose distribution in the tumour volume, while limiting the 
dose to surrounding normal tissues (Kahn 2010). This technique uses multiple gantry 
angles, and beam shapes with inversely calculated spatially varying energy fluence, 
optimised to achieve a desired dose distribution. A characteristic of IMRT is the 
ability to produce conformal distributions to targets which contain concave (i.e. re-
entrant) surfaces, these dose distributions are characterised by steep dose gradients at 
the tumour edges (Palta et al. 2003). 
 
IMRT may be delivered using compensators or MLCs. Compensators are metal 
blocks placed in the accessory mount of the LINAC treatment head that act to 
modulate the fluence of the radiation beam to the desired shape across the treatment 
field. The compensator modulates the beam to produce maximum dose to the target 




compensators prepared for their treatment from information obtained from the TPS 
(Chang et al. 2004). This method of IMRT delivery is not used commonly, with 
treatment staff having to enter the room to change compensators for each beam, and 
the cost of the attenuating material being too high to sustain this technique for large 
numbers of patients. 
 
Figure 1.4.2.1: Compensator used for IMRT delivery. The different thickness of 
material modulates the beam to increase tumour kill and decrease dose to proximal 
organs at risk (Javedan et al. 2008). 
 
Small MLC shaped apertures/segments are commonly used for IMRT delivery using 
modern LINACs. MLCs are collimation systems consisting of a high density, 
attenuating material (predominantly an alloy of tungsten) that can be ancillary to or 
may replace one or both jaws in the LINAC treatment head. The MLC system 
consists of opposed leaf pairs that can shape the field in a way similar to a jaw or in a 
way that is highly conformal to the tumour/target shape (Huq et al. 2002). Unlike 
compensators, MLCs can be driven into place automatically via computer control. 
 
 






The delivered beam at each gantry angle is subdivided into segments with uniform 
beam intensities. The segments are delivered in sequence one at a time in a way that 
the segments can build on top of one another to form spatially varying intensities 
across the field. Segments can also be delivered with different MU per segment so 
this also varies the dose delivered in each segment. The process is achieved by 
computer control of MLC segments and beam generating systems (Kahn 2010). Two 
delivery options are available for MLC delivered IMRT: dynamic MLC IMRT and 
segmental MLC IMRT.  
 
1.4.2.1 Dynamic MLC IMRT 
Dynamic MLC IMRT (dMLC) is a technique whereby the dose is delivered with the 
MLCs moving across the radiation field to shape the beam. dMLC is used for some 
IMRT deliveries and for all rotational IMRT treatments.  When the delivery involves 
dynamic movement of the leaves from one side to another, this is called dynamic 
sliding window delivery of IMRT. 
 
1.4.2.2 Static MLC IMRT 
Static MLC IMRT (sMLC) uses static beams with different MLC shapes to form a 
modulated beam. This technique of delivery is also known as Step-and-Shoot IMRT 
as the segment shape is formed with the MLC leaves, the field is delivered (shoot), 
and the beam is turned off while the next segment is being set by the MLCs (step). 
Both Siemens and Elekta LINACs use the sMLC technique to deliver IMRT 
treatments. Varian LINACs can deliver dMLC or sMLC treatments. The mode of 
IMRT delivery usually depends on the planning system used to generate the patient 
plan.  
 
1.4.3 Volumetric Modulated Arc therapy 
VMAT is an arc-based delivery approach that uses dMLC IMRT, variable dose-rate, 
leaf speed and gantry speed to achieve dose conformality to the tumour and minimise 




technique developed by Yu (1995) called Intensity Modulated Arc Therapy (IMAT), 
and by Otto (2007) called Volumetric Modulated Arc Therapy, which incorporated 
gantry speed and dose rate variability. VMAT was developed to maximise the 
number of treatment angles used (360°) for irradiation of the tumour volume in the 
shortest amount of time (approximately 30% less time than for sIMRT) (Alvarez-
Moret et al. 2010). Typical treatment times are shorter for a VMAT plan compared to 
IMRT as the treatment is a predominantly open aperture technique which hence 
requires a smaller amount of MU delivered to achieve dose coverage. Time is also 
gained due to the dynamic nature of the MLCs, and continuous delivery of dose with 
gantry rotation. VMAT treatments involving complex targets may require delivery of 
multiple arcs to achieve coverage of the PTV. This delivery increases total treatment 
time and may not provide advantages over IMRT for total treatment time. 
 
1.5 PATIENT IMAGING / TREATMENT VERIFICATION 
The positioning of a patient on the treatment bed and visualisation of internal organs 
and target volumes prior to treatment are crucial factors in the radiotherapy setting. 
Positioning of the target volume can vary day-to-day (inter-fraction motion) and also 
within the treatment time (intra-fraction motion). The ability to visualise (through 
imaging) the position of the targeted area and correct for differences between the 
time of planning and treatment is a crucial factor in the overall effectiveness of a 
course of radiotherapy. Any positional differences in a patient’s anatomy between 
planning and treatment can lead to a geometric miss of the tumour volume which 
decreases the Tumour Control Probability (TCP) and increases dose to surrounding 
normal tissues, this may lead to an increase in Normal Tissue Complication 
Probability (NTCP) of the organ at risk (OAR) (Mundt et al. 2011).  
 
Patient positioning was traditionally performed using radiographic film. This film 
was placed beneath the patient, marked for position and irradiated. The film then had 
to be processed and analysed for patient positioning purposes before the treatment 
could begin. This process took 5 - 15 minutes to perform for each patient portal film 





With the development of digital imaging technology, on-board imaging panels have 
become available for electronic patient imaging and are now standard on most 
LINACs. EPIDs are large area detectors that can be used to generate radiographic 
images with a relatively low dose of irradiation from the LINAC. The EPID image 
obtained is directly transferred to patient positioning software for comparison with 
the planned patient position. Shifts in patient position can then be applied following 
online analysis using bony anatomy or field edge matching (Khan 2010).  EPIDs 
have also been used for matching to fiducial markers implanted in the prostate or 
surrounding tissue for treatment of prostate cancer (Schiffner et al. 2007). 
 
 
Figure 1.5.1: Linear accelerator fitted with an EPID (bottom) below the treatment 
head and a KV source and a kV panel (right and left) perpendicular to the treatment 
head/radiation beam (Ravindran et al. 2007). 
 
EPIDs use the MV beam from the LINAC treatment head to create an image of the 
patient. These images can offer good bony anatomy contrast and matching, but suffer 
poor soft tissue contrast due to beam energy and penetration properties (Ravindran et 
al. 2007).  
 
To increase the contrast available for soft tissue and treatment sites such as the 
prostate, kV imagers have been implemented on modern LINACs. The kV imaging 
system consists of an x-ray tube and imaging panel placed orthogonal to the MV 




(SNR) per unit dose and low-dose volumetric imaging capabilities when compared to 
MV imaging techniques (Groh et al. 2002). KV imaging also delivers lower dose to 
the patient than MV imaging; with ~0.1 cGy for a kV CBCT compared to ~1-8 cGy 
respectively for orthogonal MV imaging for a head and neck treatment (Ding et al. 
2011). Imaging dose from MV CBCT has also been investigated by Quinn et al. 
(2011) for breast radiotherapy with doses < 4cGy measured for an 8 monitor unit 
(MU) MV CBCT image. As a result patient kV imaging can be a preferred 
alternative to MV imaging when deciding on imaging protocols due to the reduced 
risk of secondary induced cancer to radiotherapy patients (Walters 2002). 
 
Two-dimensional kV images can be acquired using the kV tube and detector 
assembly in the direction orthogonal to the LINAC treatment head and hence the 
radiotherapy beam, however when proximal organs at risk are involved the kV 
projection images can be taken by rotating the LINAC gantry containing the kV 
imager in an arc while acquiring kV projections. These projections are then 
reconstructed as a three-dimensional CBCT image for more accurate target 
localisation.  
 
kV CBCT images have become popular for prostate imaging protocols due to the 
volumetric soft tissue information and the ability to accurately match fiducial 
markers in three-dimensions. Although better contrast is offered, a single CBCT 
image can take up to a minute to acquire and the increased contrast may not be 
required for all types of treatments. It must be noted, though, that the doses to 
peripheral organs can be of concern using kV CBCT due to large volumes of normal 
tissue being irradiated (Ravindran et al. 2007). The reproducibility of CT numbers 
from kV CBCT render them more useful as image guidance images and they are not 
widely used for adaptive re-planning. kV CBCT are more often used as a trigger for 
adaptive re-planning that requires a rescan on a simulator CT device.  
 
1.6 PATIENT DOSE VERIFICATION 
The dose received by a patient to the target volume (tumour) and surrounding organ 
at risks (OARs) is required by the ICRU to be within 95 – 107% of the prescription 




specific pre-treatment verification of delivered dose using an independent MU 
checking program (3DCRT), and additional machine QA measurements of the 
patient plan (IMRT / VMAT).  
 
Patient-specific machine dose verification QA measurements are routinely performed 
with single ion chambers for point dose measurements, and with film, ion chamber 
and diode arrays for 2D dose fluence comparisons. These measurement techniques 
involve the procurement of extra equipment for a department. The implementation of 
kV imaging for image guidance and subsequent patient positioning has seen a 
reduction in the use of the EPID for this purpose. Coincidentally there has been an 
increase in the number of centres using the EPID for pre-treatment dosimetry 
measurements during the reduction of the use of the device for patient image 
guidance, with various techniques and algorithms developed by groups to implement 
the EPID into routine patient-specific dose verification QA.  
 
The use of EPID imaging panels to perform simple, vendor-independent pre-
treatment dose verification of patient-specific IMRT and VMAT plans is explored in 
this Masters thesis. An in-depth literature review on IMRT and VMAT pre-treatment 
dose verification QA is presented in Chapter 2, in particular the use of the EPID 
















2 LITERATURE REVIEW 
 
In this chapter a detailed analysis about the properties of various EPIDs are 
presented. In particular, several dosimetric properties of the devices are provided 
when the imagers are used for dose verification of radiotherapy treatment fields.  
 
2.1 PORTAL IMAGING 
Portal images are used in the radiotherapy field as one of the imaging tools in the 
IGRT and Adaptive Radiation Therapy (ART) process. An image of the patient is 
acquired in the treatment position immediately prior to a treatment fraction and 
compared to a reference image, typically a DRR. These DRRs are produced by the 
treatment planning system from the patient CT dataset for selected treatment beams. 
Portal images acquired at the time of treatment are compared to the DRRs by patient 
geometry (bone) and by MLC/jaw edge matching (i.e. treatment portal shape). Shifts 
of the patient support couch are performed based on this matching of the portal 
image and DRR to achieve the closest correlation of patient treatment position to the 
planning data (Webb 2001(a), Meyer 2007, Khan 2010, and Chen et al. 2011). 
 
 
Figure 2.1.1: DRR (left) and EPI (right) comparison for a clinical head and neck 
plan. Cross hairs on DRR and EPI denote the corresponding isocentres (Chen et al. 
2011). 
 
Portal images taken at MV energies have a reduced image quality when compared to 
diagnostic radiographs taken at kV energies. The reduced image quality is due to the 
nature of interactions of the higher energy x-rays in the patient or phantom and in the 
detector panel. The predominant process of x-ray interaction at MV energies is 




rather than atomic number, therefore at tissue-air interfaces the image quality is high, 
but for imaging higher density materials such as bones, is significantly decreased 
(Greene et al. 1997). 
 
Advantages of EPID imaging relative to conventional film for positional verification 
have been of significance and have led to the almost complete eradication of film in a 
radiotherapy setting. Advantages include faster imaging and image verification, 
computer-assisted anatomical structure matching and overlaying of acquired (EPID) 
and predicted (DRR) images, digital image processing, transfer and storage. Image 
processing available with EPID imaging includes the ability to adjust image contrast 
and add different filters to the image to optimise image quality for position 
verification (Kruse et al. 2002). Integration of computerised portal imaging systems 
with radiotherapy record and verify systems also provides significant workflow 
advantages as image acquisition and review can be performed at a single 
workstation. 
 
2.2 ELECTRONIC PORTAL IMAGING DEVICES 
At present active matrix, flat panel imagers (AMFPIs) are the most utilised type of 
EPID in radiotherapy centres. These devices consist of a large area pixelated array 
overlaid by a thin x-ray converter (metal plate and scintillator) and an electronic 
detection, acquisition, and analysis system (Antonuk 2002). The metal plate provides 
build-up for the scintillator, generating electrons and x-rays generated through the 
Compton Effect for interaction with the phosphor. The scintillator, upon interaction 
with ionising radiation, emits visible light with one interaction producing thousands 
of visible light photons (Attix 1986). The scintillator is directly coupled to a 
photosensitive layer in the AMFPI EPID for both the Siemens OptiVue 1000STTM 
and the Elekta iViewGTTM; this layer consists of 133 mg cm-2 terbium-activated 






Figure 2.2.1:  Cross-section of the Elekta iViewGTTM a-Si EPIs (Elekta iViewGTTM 
R3.02 – R3.4 corrective maintenance manual).  
 
Light incident on the photosensor causes the production of an electron-hole pair.  
The photosensor acts as a capacitive element, storing the integrated charge created by 
the electron-hole production until readout (Antonuk 2002). Commercially available 
AMFPI EPIDs consist of photosensors fabricated from hydrogenated amorphous 
silicon (a-Si:H).  
 
The AMFPI EPID pixelated array consists of thin film transistor (TFT) electronic 
circuits. These circuits contain a thin film switch connecting a capacitor 
(photosensor), consisting of a-Si:H, to the control and data circuitry. Application of 
voltage to a switch determines its conductivity. A conductive switch allows the 
integrated charge (from irradiation) to be transferred along the data circuitry to be 
read out; a switch that is not conductive allows the integration of charge in the 
capacitor when the panel is exposed to radiation. Switching of the voltage from one 
row of switches to the next in the pixelated array allows the signal to be transferred 
in the data circuitry to form an integrated image. Each complete read-out of the panel 







Figure 2.2.2:  Schematic diagram of a corner of an AMFPI EPID. Note the control 
and data circuitry surrounding each pixel element (Antonuk 2002).  
 
EPID images are usually displayed as the average of several frames, the so-called 
frame-average image. The total cumulative pixel values from an exposure can be 
obtained by integrating the frames or by multiplying the frame-average image by the 
number of frames acquired. (Chang et al. 2003). 
 
Electronic circuitry is often situated around the perimeter of the active matrix of the 
AMFPI. This provides a limit of the field sizes able to be imaged using the EPID at 
extended SSDs due to radiation damage effects on the external circuitry. Typical 
field sizes for the AMFPI at the level of the panel are approximately 41 x 41 cm2 for 
the Siemens Optivue 1000STTM (Siemens Medical Solutions, Concord, California) 
and the Elekta iViewGTTM (Elekta, Crawley, United Kingdom) and 40 x 30 cm2 for 
the Varian aS1000 (Varian Medical Systems, Palo Alto, California). 
 
The contribution of backscatter radiation from the detector arm has been examined 
by Greer et al. 2007 for Varian machines. Robotic arm backscatter is negligible for 
Siemens and Elekta units due to a lower density arm material, and the more uniform 
material directly behind the detector compared to the Varian steel arm. As a result, 
this thesis does not examine the effect of robotic arm backscatter due to the use of 




2.2.1 EPID Calibration 
EPIDs require a calibration to correct the panel for LINAC beam characteristics and 
inherent detector characteristics to produce the highest quality image for patient 
positioning. The calibration process involves the acquisition of a dark field (DF) 
image and a flood field (FF) image that are used in a calibration equation and 
subsequently applied to all images acquired with the portal imager.  
 
The DF signal is obtained by acquiring an image over the entire area of the EPID in 
the absence of a radiation beam. The pixels in this DF image correspond to electronic 
noise inherent in the detector system. The DF is influenced by the ambient 
temperature (McDermott et al. 2003) and the long term stability has been seen to 
vary over time due to radiation induced damage to the array (Louwe et al. 2004).  
 
The FF is obtained by acquiring an image with the EPID in the presence of a uniform 
radiation field over the entire detection area of the panel. This image is used to 
correct for pixel sensitivities, and create a uniform response over the entire panel 
area to a radiation beam. The flood field effectively removes variations in the beam 
intensity across the panel area caused by the dose profile horns. This FF calibration 
acts to optimise patient imaging contrast by eliminating the variations in the dose 
profile. The FF calibration is acquired at regular intervals following manufacturer 
recommendations to maintain image quality. The calibration process ensures any 
pixels that may have undergone radiation induced changes or mechanical and 
electrical damage are identified with and their response scaled appropriately to 
produce a uniform image across the detector. 
 
The calibration image can be obtained by dividing the pixels in the raw image (Iraw) 
(x, y) by those in the FF image (IFF) (x, y), and subtracting the DF image from both 
measurements (IDF) (x, y). The DF image can be used from the time of calibration, or 
























Calibration images are recommended to be taken with each nominal beam energy for 
a LINAC using the largest field size possible. This is due to the variation in beam 
intensity across the field and differences in beam profiles between energies (Herman 
et al. 2001). 
 
2.3 DOSIMETRIC CHARACTERISTICS OF EPIDS 
A significant amount of research has been performed examining the dosimetric 
characteristics of EPIDs. Antonuk (2002) and van Elmpt et al. (2008) have provided 
in-depth literature reviews on the development, use and characterisation of EPIDs for 
clinical dosimetry since clinical implementation. 
 
2.3.1 Pixel Sensitivity 
Individual pixels in EPID panels have responses that vary from the central axis pixel. 
Pixel sensitivity is defined as the EPID pixel response to a uniform beam across the 
detector and has been examined in detail by Greer (2005). The pixel sensitivity is a 
parameter that is independent of the gain calibration (which corrects for off-axis 
response of the panel), and can be applied to the whole panel for calibration and 
imaging purposes. The pixel sensitivity is described by Greer (2005) as a change in 
sensitivity of the individual pixels in an EPID panel, and the off-axis response as an 
energy-dependent parameter relating to the phosphor layer. By irradiating an EPID in 
different positions across the panel by a 10 x 10 cm2 field, a variation in EPID pixel 








Figure 2.3.1.1: EPID pixel sensitivity map across the central axis of a Varian EPID 
(Greer 2005). 
 
This pixel sensitivity was used to generate a polynomial that was applied to all 
subsequent raw EPID images to improve off-axis pixel response for dosimetry 
purposes. This method was implemented by Greer (2005) to raw-EPID images. Other 
methods to model the off-axis response of the EPID are presented by Parent et al. 
(2007) using Monte Carlo simulation. 
 
2.3.2 Linearity 
The dose linearity of EPIDs has been studied by Budgell et al. (2005), and Winkler et 
al. (2006). Linearity of EPIDs for low MU deliveries has been attributed to the 
ghosting effect, whereby charge carriers become trapped in defect levels. The 
ghosting effect is examined in section 2.3.3.  Comparisons of the dose response for 
the EPID and ion chamber measurements were performed for 1 – 40 MU irradiations 
(Budgell et al. 2005). The dose response of the EPID was determined from 
evaluation of the central 50 x 50 pixels in the image. For both ion chamber and EPID 





Figure 2.3.2.1: Linearity comparison between the EPID and ion chamber for 6 and 8 
MV photon beams for 1 – 100 MU irradiations (Budgell et al. 2005).  
 
Ion chamber results demonstrate linearity within 2% for a 1 MU segment for both 6 
and 8 MV beams. The ion chamber is used as a reference dosimeter with known 
linear dose response behaviour for comparison with the EPID. EPID results 
demonstrate a lack of linearity for low MU deliveries, in particular the results show 
greater loss of linearity with an increase in beam energy. The decrease in EPID 
signal for lower MU deliveries has been attributed to ghosting and image lag effects 
by Budgell et al. (2005), Mail et al. (2005), Winkler et al. (2005) and McDermott et 
al. (2006).  
 
Winkler et al. (2006) performed an inter-comparison of 11 Elekta iViewGTTM aSi-
EPIDs. The panels were found to be non-linear with dose for MU deliveries less than 
4 MU, with deviation of 5.5% for a 6 MV beam, and 7% decrease for a 25 MV 
beam. For irradiations between 4 and 100 MU the linearity was found to be within 
0.35% (Winkler et al. 2005). Deshpande et al. (2011) performed an inter-comparison 
of three Siemens a-Si EPIDs with a variation of 2% between EPID and ion chamber 
measurements down to a 1MU delivery. 
 
The contribution of LINAC start-up fluctuations was also analysed by Winkler et al. 
(2006), allowing a detector-only linearity analysis by elimination of LINAC 




3.5% for a 25 MV beam for the Elekta iViewGTTM panel for delivered MUs from 1-
1000.  
 
2.3.3 Ghosting and image lag 
Ghosting and image lag occurs in EPID dosimetry due to the properties and 
construction materials of each panel. Ghosting is the change of the EPID pixel 
sensitivity to radiation due to trapped charges as a result of previous exposures to the 
panel (McDermott et al. 2003) and can be attributed to a change in electric field 
strength in the a-Si layer of the panel. This change in field strength creates a change 
in sensitivity of the a-Si layer and hence image acquisition.  
Image lag is the residual signal / charge from a measurement frame that was read out 
or processed in subsequent image frames (i.e. the charge is read out in subsequent 
frames, not the frame in which the charge was actually collected). This charge results 
in an offset of the charge readout for the next reading/measurement made by the 
panel (McDermott et al. 2003, Mail et al. 2007). In the first few acquisition frames 
(following beam-on) no residual charge exists in the panel from previous 
irradiations/previous frames. As acquisition continues, residual charge from previous 
frames is trapped in the panel and builds until equilibrium is reached. Pre-irradiation 
of the EPID is often performed such that the non-linearity associated with this 
phenomenon is reduced (Budgell et al. 2005). 
 
Numerous studies have been performed on all vendor EPID panels to assess the 
effect of image lag and ghosting. An inter-comparison of the Siemens, Elekta and 
Varian EPID panels by McDermott et al. (2006) demonstrated that all a-Si EPIDs 
were subject to ghosting for small MU deliveries, with up to 5% variation when 
examining EPID signal per MU.  
 
Image lag and ghosting effects have been quantified by a two-image technique, 
where the panel is irradiated with a small field, with an immediate irradiation of a 
different sized field. A ratio is taken with another acquired image of the larger field 




difference in signal for Varian panels (Van Esch et al. 2004); a 1.6% difference was 
found for Siemens panels (Nijsten et al. 2007). 
 
Image lag and ghosting was investigated one step further using the two-field 
technique for Elekta iViewGTTM panels as a function of time between irradiations of 
the different field sizes, and with different MU irradiations of the fields (Winkler et 
al. 2005). It was found that an increased dose delivered to the first field with 
minimum time between subsequent irradiation caused an 8.9% difference in EPID 
response. 
 
Figure 2.3.3.1: EPID dose profile obtained for a 15x15 cm field with (solid line) and 
without (dotted line) pre-irradiation of 500 MU in a 5x5 cm field. The ratio of dose 
profiles is presented in the insert. (van Esch et al. 2004). 
 
2.3.4 Segment-to-segment reproducibility 
Budgell et al. (2005) examined the reproducibility of the EPID response for low and 
fractional MU segments. The reproducibility was determined using a single IMRT 
prescription containing up to 20 segments of 1 and 2 MU deliveries. An IMRT 
prescription was used due to possible delivery differences between single exposures 








 Table 2.3.4: Reproducibility for a 20 segment IMRT prescription including analysis 
of the whole prescription and the last 15 segments (Budgell et al. 2005). 
 
Greater variation was observed in the first 5 segments of the IMRT prescription 
compared to the remaining measured segments. The variation was observed to be 
reproducible with repeated panel irradiations. This was attributed to the start-up non-
linearity of the EPID caused by ghosting, and the initial ramp up of the LINAC. 
 
2.3.5 Short-term and long-term reproducibility 
Reproducibility of EPID panels has been examined for short-term and long-term 
reproducibility with similar results obtained for all vendors. 
 
Short term panel reproducibility was assessed over a set of repeated measurement 
with an EPID panel in a single measurement session. Reproducibility was tested for 
each of the different panels with the following maximum deviations from baseline 
values established at the time of panel commissioning: Varian aS500 = 2.0% (Van 
Esch et al. 2004), Elekta iViewGTTM = 0.5% (Winkler et al. 2005), Siemens Optivue 
500/1000STTM = 0.7% (Nijsten et al. (2007). Deshpande et al. (2011) studied the 
short term (10 consecutive measurements) and long term (12 month period) 
reproducibility of 3 Siemens EPIDs with maximum 0.5% and 1.0% deviation from 
baselines respectively.  
 
2.3.6 Field size dependence 
The change in output at the centre of a radiation field changes as a function of 
irradiated field size. The variation in dose is the product of the phantom scatter factor 
(Sp), the amount of scattered radiation contributing to dose from the amount of 




scattered radiation resulting from the treatment head of the LINAC (measured using 
a mini-phantom or ion chamber with build-up cap i.e. no phantom material present).  
 
The change in output as a function of field size will differ to that of an ion chamber 
in water due to the construction of the EPID and the non-water equivalence of the 
materials contributing to different scatter conditions. These materials include metal 
layers such as the Cu build-up plate, and the phosphor screen. These metal 
components act to decrease the lateral scatter distance of the incident radiation 
causing a decrease in penumbral width in comparison with a water phantom (Lee et 
al. 2009), and cause an over-response to low-energy photons due to the photoelectric 
effect of the high atomic number of the phosphor (Greer 2005). Gustaffson et al.  
(2009) had previously investigated the effect of different materials used in EPID 
panels on the resulting dose profiles and output factors obtained. It was found that 
different materials had a profound effect on both profiles and output factors, leading 
to the requirement that each panel must be characterised prior to use.  
 
The EPID scatter factor (Spe) is equivalent to the phantom scatter factor described 
above however it is the scatter contribution from the EPID panel (due to non-water 
equivalent construction materials) measured as a function of field size. The EPID 
scatter factor has been measured by Greer and Popescu (2003), Winkler et al. (2006), 
Nijsten et al. (2007), Van Esch et al. (2007), and Deshpande et al. (2011) with a 
maximum difference of 9% found between ion chamber measurements and the 
EPID. The largest differences were observed in small field sizes, where a 







Figure 2.3.6.1: Field size response of 3 Siemens EPID panels with comparison to ion 
chamber measured response for a (a) 6 MV and (b) 18 MV photon beams 
(Deshpande et al. 2011). 
 
2.3.7 EPID Detection methods 
Current LINAC and EPID designs work on the detection of x-rays indirectly. Indirect 
detection means that the x-ray is converted to light via a scintillator for detection by 
the photodiode array. Various studies have been conducted to assess the suitability of 
direct detection (x-ray detected without conversion to light) using the EPID.  
 
Direct detection EPIDs were constructed by Vial et al. (2008) to create a water 
equivalent panel for dose verification and comparison. For both 6 and 18MV the 
direct detection panel gave equivalent doses to within 2% for both 6 and 10 MV 
when compared to ionisation chamber measurements. The modified direct EPID 
model provides water equivalent dose response but decreased image contrast due to 





Figure 2.3.7.1: Comparison of normalised dose profiles (cross-plane) for 6MV flood 
field exposures measured with direct and indirect detection EPIDs (corrected for 
pixel sensitivity) and an ion chamber (Vial et al. 2008). 
 
All properties of the EPID panel in response to radiation fields must be fully 
understood and characterised before the imaging device can be implemented into a 
radiotherapy department for quantification of dose and in particular for the QA of 
IMRT fields. 
 
2.4 IMRT / VMAT DOSE VERIFICATION QUALITY ASSURANCE 
IMRT and VMAT plan verification is complex in nature. This complexity arises 
from factors such as irregularly shaped and sized fields, the presence of small MU 
segments, high dose gradients throughout the treatment fields and the off-centre 
positioning of segments for IMRT treatments (Ezzel et al. 2003, ICRU report 83, 
2010), with the added complexity of variable gantry speed, leaf speed, and variable 
dose-rate for VMAT treatments (Bedford et al. 2009). As a result there has been 
numerous studies looking at the optimum treatment measurement methods and 
reporting criteria suitable for IMRT treatments. Measurement of IMRT fields in high 
dose and low dose gradient regions have been recommended to be measured in a 
similar fashion to 3DCRT treatments. However these methods (generally using a 
point detector i.e. ionisation chamber) do not work optimally in regions of low doses 





The most common method used for IMRT dosimetry is that of gamma analysis, first 
devised by Low et al. in 1998. Gamma analysis involves the fusion of distance-to-
agreement (DTA) and percentage dose difference (%DD) criteria between a 
reference dose plane and an evaluated dose plane. Typically the reference dose plane 
is calculated and the evaluated dose plane is measured. The DTA searches a 
specified area from a point in the reference plane to the evaluated plane to find the 
closest point equal in dose. The %DD compares the dose at a point in the evaluated 
plane to the corresponding point in the reference plane.  The gamma analysis 
technique of dose comparison in highly modulated IMRT fields has been described 
in a paper by Low et al. (2003), defining the gamma (γ) quantity as the minimum 
difference in the renormalised multidimensional space between the evaluated 
distribution and the reference point. 
 
For a specific point in the reference plane, the dose distribution is searched in the 
evaluated plane to locate the corresponding point. If the point is within a specified 
distance to the reference point and within a specified percentage of the maximum 
reference dose a pass or fail can be reported.  
 
 
Figure 2.4.1: Geometric representation of gamma analysis dose evaluation criteria. 
The dose difference and the distance to an agreement point is evaluated between the 





Basran et al. (2008) has stated clinical selection criteria for the gamma analysis 
comparison of IMRT fields. A search distance or DTA of 3mm and dose difference 
of 3% of the maximum dose is reported. These parameters are chosen due to the 
increased need for plan delivery accuracy of the small, highly-modulated segments 
of an IMRT field. 
 
Variation of the required gamma analysis pass rate occurs between clinics for IMRT 
plan approval. A widely accepted value of 90%  of points passing the 3 mm, 3% 
gamma criteria for all points that are above 10% of the maximum dose is employed 
in many clinics (Antonuk 2002). Basran et al. (2008) states that a pass rate of 95% is 
required for IMRT plan approval, with a lower 88% pass rate required for head and 
neck cases. Variation in the pass rate of one treatment plan can arise from the type of 
dose comparison used. The analysis of absolute dose is recommended in IMRT field 
verification due to the combination of the intensity modulation and the dose output 
over the entire field. It is possible when performing relative dose analysis to miss 
significant errors in overall delivered dose to the entire field. 
 
Ezzel et al. (2009) recommend caution is taken when using a per-field gamma 
analysis for the sole verification of IMRT fields. A search area of 3mm in all 
directions can decrease the detection efficiency of dose delivery error in a composite 
IMRT field, when one or more individual segments may include delivery error but 
the effect is undetected due to the large area available to find a point of dose 
matching between reference and evaluated fluence maps. Nelms et al. (2011) tested 
24 clinical head and neck IMRT cases with 4 different dose errors introduced. 
Analysis was performed using gamma criteria of 3% / 3 mm, 2% / 2 mm, and 1% / 1 
mm. Results provided information that common acceptance criteria for gamma 
analysis of IMRT fields were not accurate in prediction of dose errors in a measured 
plan. Gamma analysis is however, still widely used in the clinic to test delivery of 
IMRT beams compared with the treatment plan due to the ease of comparison of 
doses and the ability see areas that fail different criteria set by the user. 
 
As a result of the complex nature of IMRT and VMAT treatment beams, two-




field comparison. Two-dimensional detectors such as film (radiographic and 
radiochromic), ion chamber arrays, diode arrays and EPIDs are commonly 
recommended and used to verify IMRT fields (Ezzel et al. 2002, ESTRO Booklet 9 
2008, ICRU Report 83 2010, ASTRO practice guideline for IMRT 2011). Phantoms 
using multiple planes of detectors such as the Scandidos Delta4 diode array 
(Scandidos, Uppsala, Sweden) have also been produced for the verification of 
VMAT in order to provide 3D reconstructed measured dose distributions for 
comparison with planned doses.   
 
2.4.1 Quality Assurance using Film 
Radiographic film has frequently been employed to verify IMRT fluence maps by 
obtaining a two-dimensional dose distribution of a given radiation field (Olch 2002). 
The high spatial resolution of radiographic film provides accurate dose reporting 
over the entire field of view for the treatment area. Zhu et al. (2002) reports a 
maximum 2 mm difference between film measurements and those obtained with an 
ion chamber in a scanning water phantom in high dose gradient regions. In low dose 
gradient areas, a maximum difference of 1% was observed.  
 
The introduction of radiochromic film into the market has seen an increase in the use 
of film for dosimetry and for pre-treatment verification of IMRT. Extensive literature 
exists examining properties of radiochromic film and applications for its use. The 
AAPM Task Group 55 provide recommendations on radiochromic film dosimetry 
(Niroomand et al. 1998), however this report does not include the newer film types 
that have improved performance as dosimeters. Radiochromic film dosimetry for 
radiotherapy beams is appealing due to its high spatial resolution, energy 
independence in MV energies (Butson et al. 2009), tissue-equivalence (ISP 2009), 
and due to the self-developing nature of the film. Radiochromic film has 
subsequently been used for IMRT dose verification QA (Ziedan et al. 2006, Chung 
2009, Kairn et al. 2011) with gamma analysis results for film dosimetry matching 





Film measurements for IMRT and VMAT dose verification QA are complex due to 
the delayed nature of read-out and technical difficulties to accurately convert the 
optical density of the film to absorbed dose, and potential difficulties associated with 
flatbed scanners (scatter, positioning and polarisation).  
 
2.4.2 Quality Assurance with Ion Chamber / Diode Arrays 
Arrays of ion chambers and diodes are commercially available and frequently used 
for clinical IMRT and VMAT dose verification QA.  The array is advantageous due 
to the accuracy of dose reporting by the use of ion chamber measurements, and the 
ability to measure an entire treatment field due to multiple chambers present within 
the device. Studies previously undertaken with ion chamber arrays show that there is 
a limit to the accuracy of fluence map reporting due to the spatial separation of the 
individual ion chambers (Amerio et al. 2004, Spezi et al. 2006, Tyler 2008).  
 
Methods to increase the sampling capabilities of the arrays for use in highly 
modulated and complex IMRT fields have been developed by Spezi et al. (2006) and 
Tyler (2008). Implementation of these methods are time consuming and require 
movement accuracy well within 0.5 mm and software manipulation and summation 
of multiple measured data to obtain a higher resolution fluence map for accurate 
comparison. As a result the array and summation methods would not be suited for 
clinical IMRT dose verification.  
 
2.4.3 Quality Assurance using the EPID 
The number of patients prescribed IMRT radiotherapy for treatment of their cancer 
has increased rapidly in Australia over the past few years with 6.5% of new 
radiotherapy courses being treated using the technique in 2010 (RANZCR 2011). 
Following the introduction of the technique at the Prince of Wales Hospital in 2006, 
and at Liverpool Cancer Therapy Centre in 2008, patient loads have increased, 
causing an increased strain on resources and time due to patient specific QA routines 
used. Therefore there is a need for a fast, more efficient IMRT dose verification QA. 
The EPID has been suggested as a solution due to the ability to collect and analyse 





The use of EPIDs for QA and IMRT dose verification has been increasing in the 
previous few years. Publications by Budgell et al. (2005) and van Elmpt et al. (2009) 
discussed the use of the EPID for regular IMRT dose verification QA. The method of 
pre-treatment QA is described as fast and therefore beneficial in clinics with high 
patient-throughput. In the IMRT dose verification QA method, a simple ‘dummy 
run’ of the treatment is performed with no phantom or patient in the beam. The 
planar dose maps are collected by the EPID and then used for online, automated 
comparison with the TPS. The ability for the EPID to detect MLC positioning errors, 
incorrect data transfer of the treatment plan, and errors in the treatment delivery, 
make the EPID a favourable online dosimetric tool for routine clinical QA and for 
IMRT dose verification QA methods (Clarke and Budgell 2008). 
 
Review of various approaches to EPID dosimetry for IMRT and VMAT dose 
verification QA, and methods currently used are discussed in section 2.5.  
 
2.5 IMRT VERIFICATION USING EPIDs 
Different methods have been derived and used in practice for the verification of 
IMRT fields with EPIDs. These methods are based on EPID measurements with 
pixel-to-dose conversion, modelling of predicted EPID fluences and by Monte-Carlo 
simulations. 
 
Currently, two commercial systems exist for EPID dose verification QA EPIDose 
(Sun Nuclear Corporation, Florida, USA), and Varian Portal Dosimetry (Varian 
Medical Systems, Palo Alto, USA). These systems use algorithms to calculate the 
EPID predicted dose for a radiation field and compares them to the radiation field 
measured with the EPID. The EPID image can also be imported into the software and 
converted to dose for analysis and comparison with a TPS planned fluence.  
 
Independent IMRT and VMAT dose verification QA methods have been developed 
by a number of people using different EPID models and vendor types. Most methods 
employ complex post-processing corrections applied to the EPID image to account 




previously. Two methods have been developed; transmission methods (with a patient 
or phantom between the source and the EPID) (Partridge 2002, McDermott et al. 
2007, Nijsten et al. 2007, Mans et al. 2010, and Pecharromán-Gallego et al. 2011) 
and non-transmission methods (without a patient or phantom between the source and 
the EPID) (Grein 2002, Siebers et al. 2004, Van Esch 2004, Greer et al. 2007, Nijsten 
et al. 2007(b), Lee et al. 2009). The TPS has been used by Khan et al. (2008) to 
produce an EPID dose model that simulates the measured field on the EPID for 
planned IMRT fields and allows a comparison between measured EPID and 
modelled EPID 2D fluences. 
 
2.5.1 Transmission methods 
Transmission methods involve measurement of the photon fluence with the EPID 
with an object (phantom or patient) between the emitted photon beam and the panel. 
Numerous studies have been presented using the transmission methods to measure 
the photon fluence for IMRT beams in-vivo or using a phantom for pre-treatment 
verification using back-projection algorithms to project the EPID measured dose 
back into a phantom or onto the patient CT scan for comparison with planning data. 
 
McDermott et al. (2007), Mans et al. (2010) and Pecharromán-Gallego et al. (2011) 
have presented transmission QA techniques that use the measured EPID image and 
in-house back-projection techniques to calculate the EPID dose onto a phantom.  
 
Pecharromán-Gallego et al. (2011) has similarly used back-projection on EPID 
measurements. A model based on measurements performed to assess the 
characteristics of the EPID was established by the group, with this model used to 
project the patient doses based on the beam shapes onto the patient plan. The model 
included beam hardening and off-axis effects of the panel. It was established that the 
model could be used for clinical verification of IMRT and showed high gamma 
passing rates. 
 
Mans et al. (2010) utilised a back-projection technique to reconstruct in-vivo 




back-projection algorithm incorporates the panel scatter properties, the inverse-
square law, and attenuation of the radiation beam between the exit of the radiation 
from the patient or phantom to the plane of reconstruction. Multiple reconstruction 
planes can be calculated with a 3D dose calculated for the patient treatment.  
 
McDermott et al. (2007) used the EPID images back-projected into a slab phantom to 
compute the agreement (using gamma analysis) between measured and planned 
prostate IMRT plans. EPID doses were compared to radiographic film with over 98% 
agreement found when compared to the EPID.  
 
The above-mentioned transmission measurements can use a convolution approach to 
convert the measured EPID fluence to a dose distribution in a homogenous phantom. 
The convolution method uses a scatter kernel applied to the measured fluences to 
account for the differences in the scatter conditions of the EPID compared to a 
homogenous water phantom. 
 
Convolution techniques have been presented by a number of authors. These 
convolution kernels are applied to fluences generated in the TPS for comparison to 
the EPID measured fluence map, or conversely, applied to the measured dose map to 
match the TPS generated dose distribution.  
 
2.5.2 Non-transmission methods 
Non-transmission methods involve measurement of a fluence using the EPID with no 
object between the detector and the source of photons (treatment head). Previous 
studies have used this method for comparison of pre-treatment measured fluences 
(with the EPID), to planning system-generated fluences. 
 
Siebers et al. (2004) used non-transmission measured EPID fluences and Monte 
Carlo calculations to reconstruct a 2-D dose plane at the level of the detector. The 
EPID geometry was modelled using Monte Carlo simulations and applied to the 




panel. An IMRT test field was used with 99% of points passing gamma analysis with 
2%, 2mm criteria. 
 
An approach by Van Esch et al. (2004) used measured EPID fluences of open fields 
to modify a dose calculation algorithm in a commercial TPS (Varian Cadplan) to 
predict the portal dose distribution obtained for treatment fields with the EPID. The 
use of EPID measurements for beam data acquisition effectively eliminated any post-
processing scatter kernel corrections due to non-homogeneity. The predicted portal 
dose image (PDI) was obtained using the TPS for generation of PDIs for IMRT 
treatment fields. PDIs were exported and directly compared to measured EPID 
fluences with 3%, 3mm agreement between PDI and measured EPID fluences. Other 
studies have used this method of PDI generation for EPID IMRT dose verification 
QA with high gamma analysis agreement rates (Warkentin et al. 2003 and van 
Zijtveld et al. 2006). This method does not reflect the actual dose to the medium 
(water) when the fluence is compared to planning system dose fluences, and relies on 
the correct application of a scatter convolution kernel (simulated by Monte Carlo 
methods) for accurate results. 
 
Chytyk et al. 2009, 2013 developed a model to predict the EPID fluence at the level 
of the panel for measured EPID fields. The model was used to calculate the predicted 
EPID fluences with those physically measured with an EPID for 20 IMRT plans with 
a mean of 96.6% of pixels passing the gamma criteria set of 2%, 3mm.  
 
A simplified approach to IMRT dose verification QA with a direct comparison from 
EPID to dose at an equivalent depth in a water phantom was presented by Lee et al. 
(2009).  The aim of the approach was to create a simple pre-treatment verification for 
IMRT plans, where the plan is delivered to the EPID (using non-transmission 
methods) and compared to the TPS. EPID measurements were also compared to 
measurements obtained with a two-dimensional diode array (MapCHECK®, Sun 
Nuclear Corporation, Melbourne, FL) and with radiographic film, showing good 
agreement between the EPID image, the TPS and other dosimetry methods (Lee et al. 




only. The research presented in this thesis is based on the work of Lee et al. (2009), 
and applied to other vendor systems and treatment techniques. 
 
EPID images were obtained for different field sizes and compared to ionisation 
chamber measurements at different depths in water. An equivalent depth was found 
where the output factors for the EPID matched that in water. Profile comparisons 
were then made with an off-axis correction applied to the EPID. A calibration of 
EPID pixel value to dose was then performed before verification and testing of 
IMRT fields. 
 
Figure 2.5.2.1: Change in dose resulting from a change in MLC field size for a 
Varian as500 EPID: (a) comparison to dose reported for an ion chamber at different 
depths on the beam CAX, (b) comparison to dose reported for an ion chamber at d=5 
cm in water on the beam CAX (Lee et al. 2009). 
 
An equivalent depth of 5cm was determined for the 6 MV and 3 cm for an 18 MV 
beam between EPID and ion chamber measurements for field size factor 
comparisons. These reference depths were then used for application of an off-axis 
ratio to the EPID image for treatment field verification, with the off-axis ratio values 





The central 9 x 9 pixels of a 100 MU reference 10 x 10 cm2 field size measured by 
the EPID were averaged and converted to absorbed dose using a pixel to dose 
calibration factor. The calibration factor was calculated using the ionisation chamber 









     (2.5.2) 
 
Using the calibration factor to convert EPID pixel values to dose, more complex 
treatment fields and patient IMRT treatment plans were compared between EPID and 
TPS generated dose planes at the reference depth (equivalent depth in water). 
 
EPID measured profiles were compared with measurements obtained with 
radiographic film and the MapCHECK® device. Comparisons and analysis were 
performed using gamma analysis criteria of 3 %, 3 mm with a 10% of maximum 
dose threshold. Agreement between the TPS and the EPID for IMRT dose 
verification was 97.0 ±0.3 % for a prostate plan and 97.5 ± 1.8 % for a tonsil plan 
using 3 %, 3 mm gamma criteria. The method produced by Lee et al. (2009) is 
effective in producing a relatively simple IMRT dose verification process using an 
EPID.  
 
2.5.3 EPID modelling using the TPS 
Khan et al. (2008) used the Pinnacle3 treatment planning system (Philips Medical 
Systems, Madison, USA) to model the Varian aS500 EPID response to 6 MV photon 
beams. Open square and rectangular fields were measured with the EPID, using the 
measured EPID profiles and output factors to create a 6 MV EPID beam model in the 
TPS. This beam model was used on patient clinical IMRT plans to predict the 
fluence measured by the aS500 EPID for pre-treatment dose verification QA. This 
method provided gamma analysis agreement >95 % using 3 % / 3 mm criteria for all 
measured fields and eliminated the need for complex scatter corrections of the 





The requirement for fast, accurate verification of IMRT fields using a simple vendor-
independent model forms the basis of this work. The requirement for accurate 
gamma analysis when comparing measured and planned doses is also studied with 
varying degrees of modulations added into fields to determine the usefulness of 
gamma analysis in IMRT and VMAT dose verification QA. 
 






























This research project involved the use of materials and equipment in the radiotherapy 
department including LINACs, amorphous silicon EPIDs, a commercially available 
two-dimensional diode array, treatment planning software and point dosimeters.  
 
3.1 LINEAR ACCELERATORS AND EPIDS 
Most modern LINACs are standard equipped with an EPID for patient imaging. 
EPID designs are different between vendors and as a result, panels for a Siemens 
Oncor ImpressionTM (Siemens Medical Solutions Erlangen, Germany) and an Elekta 
AxesseTM (Elekta CMS Crawley, UK) LINACs were characterised for dosimetry.  
 
3.1.1 Elekta AxesseTM LINAC and iViewGTTM a-Si EPID 
An Elekta AxesseTM LINAC equipped with a Beam Modulator (BM) treatment head 
was used for measurements. The AxesseTM at the Prince of Wales Hospital is a dual 
mode LINAC with maximum nominal energies of 10 MV X-rays and 18 MeV 
electrons.  
 
The BM MLC replaces both collimator jaws with an 80 leaf MLC. The BM has a 
maximum field size of 16 x 21 cm, and a 4mm leaf width projected at the isocentre. 
The BM is capable of full interdigitation of the leaves across the 21 cm field width. 
Due to the limitations of the MLC size, the BM is not able to create a 10 x 10 cm2 
field size, hence a 10.4 x 10.4 cm2 field is used as the reference field size for this 
LINAC. 
 
An iViewGTTM a-Si EPID (Perkin-Elmer number XRD 1640 AG5) is attached to the 
rotating gantry of the AxesseTM by a motorised arm directly beneath the treatment 
head and perpendicular to the delivered treatment beam. The motorized arm is used 
to extend and retract the EPID for patient imaging before or during treatment. 
Motorised retraction is essential to minimize radiation damage to the electronics 
surrounding the flat panel that may be induced as a result of large treatment field 





The EPID has an active detection area of 41 x 41 cm2 at 160 cm SSD, projecting to 
25.65 x 25.65 cm2 at the level of the machine isocentre. The active detection area 
consists of 1024 x 1024 detector elements with a pitch of 0.4 mm. The EPID has a 
fixed SSD of 160 cm available for imaging. The iViewGTTM acquires images as 
frames where a frame is a complete readout of the detector area. The iViewGTTM has 
a frame acquisition rate of 320 ms (3.1 frames per second). 
 
 
Figure 3.1.1: Elekta AxesseTM linear accelerator and iViewGTTM EPID at the Prince 
of Wales Hospital. 
 
3.1.2 Siemens PrimusTM/OncorTM LINAC and OptiVue 1000STTM a-Si EPID 
Two Siemens LINACs at the Prince of Wales Hospital were used in this research 
project. The Siemens PrimusTM and Siemens Oncor ImpressionTM LINACs are dual 
mode LINACs with clinical operating maximum nominal energies of 10 MV X-rays 
and 21 MeV electrons. Each machine is capable of treatment options from 3D 
Conformal Radiation Therapy (3DCRT), to IMRT and IGRT. 
 
The PrimusTM and OncorTM have different MLC configurations. The PrimusTM has 




isocentre plane, with the inner 27 leaves having a projection of 1 cm.   The Primus 
LINAC MLC design retains the use of the upper collimator jaw and replaces the 
lower collimator jaw with the MLC. The leaf-ends are flat and double-focused on the 
x-ray source so that the leaf-ends and sides align with beam divergence in one 
dimension (1D) (Metcalfe et al. 2007).  
 
The OncorTM is equipped with a 160 leaf MLC consisting of 80 opposed leaf pairs. 
Each leaf is of the same width and has a projection of 4 mm at the isocentre.   The 
Oncor LINAC MLC design also retains the use of the upper collimator jaw and 
replaces the lower collimator jaw with the MLC.  
 
Both Siemens LINACs are able to achieve a 40 x 40 cm field size at isocentre, with 
the MLC leaves allowed to travel from a fully retracted position to 10 cm across the 
beam central axis on the PrimusTM (Klien et al. 2001), and to 20 cm across the 
central axis on the OncorTM.  
 
OptiVue 1000STTM AMFPI EPIDs (Perkin-Elmer number XRD 1640 AG9) are 
attached to the gantry of the LINAC on a motorised arm directly beneath the 
treatment head. The motorized arm is used to extend and retract the EPID for patient 
imaging before or during treatment. Positioning accuracy of 2 mm and repeatability 
of 1 mm for the EPID is reported by Siemens Medical Solutions (2007) for the 
robotic arm.  
 
The EPID is an a-Si detector (like the Elekta iViewGTTM) and has dimensions of 672 
x 599 mm with an active detection area of 41 x 41 cm2 at 160 cm SSD, projecting to 
25.65 x 25.65 cm2 at the level of the machine isocentre. The active detection area 
consists of 1024 x 1024 detector elements with a pitch of 0.4 mm. A spatial 
resolution of 0.41 line pairs per mm has been reported by Siemens (2007). The 
OptiVue 1000STTM acquires images as frames where a frame is a complete readout 
of the detector area. The OptiVue 1000STTM has a frame acquisition rate of 143 ms 





Different source-to-detector distances of the EPID can be achieved with the Siemens 
panels. Movement and positioning for detection is allowed in the range from 115 cm 
SSD to 160 cm SSD. At the Prince of Wales Hospital for LINAC QA and patient 
imaging, the EPID is used at a distance of 145 cm SSD. 
 
 
Figure 3.1.2: Siemens Oncor ImpressionTM linear accelerator and OptiVue 
1000STTM EPID at the Prince of Wales Hospital. 
 
3.2 DOSIMETERS 
3.2.1 Ionisation chambers 
Various ionisation chambers were used in this research to validate each EPID panel 
for use as a reliable dosimeter for radiotherapy beams. 
 
Small volume CC04 (0.04 cm3 inner volume) and CC13 (0.13 cm3 inner volume) 
thimble ionisation chambers (Scanditronix-Wellhöfer, Schwarzenbruck, Germany) 
were used for measurement of output factors and field profiles. The CC04 ionisation 
chamber was used for all field sizes less than 4 x 4 cm2 due to volume effect 
limitations of larger ion chambers in these smaller fields (Laub and Wong 2003, Das 





A Farmer-Type NE 2571 thimble ionisation chamber was used for EPID scatter 
factor determination. This chamber was used due to the use of a mini-phantom with a 
fixed insert for the NE 2571 chamber for Sc measurements. The NE 2571 chamber 
has a 0.6 cm3 inner volume with graphite wall and central electrode (IAEA TRS-398 
2004). 
 
3.2.2 MapCHECK® 2D diode array 
The verification of high dose gradient fields requires detectors that are sufficiently 
small enough to limit the volume effect on measured fields and segments (Laub and 
Wong 2003, Cadman et al. 2005). 
 
At the Prince of Wales Hospital, a MapCHECK® two-dimensional diode array is 
used for routine pre-treatment IMRT delivery verification. The MapCHECK® has a 
detection area of 22 x 22 cm2, with 445 diodes encased at an equivalent water depth 
of 2cm from the detector surface.  Each diode is 0.8 x 0.8 mm2 in size, with 7.07 mm 
spacing between adjacent diodes in the central 10 x 10 cm2 and 14.04 mm spacing in 
the area outside the central 10 x 10 cm2 region. 
 
 
Figure 3.2.2.1: Detector spacing diagram for the MapCHECK® diode array (from 
manufacturers website). 
 
The MapCHECK® array is used at the machine isocentre perpendicular to the 
treatment beam with all IMRT and VMAT beams set to have Gantry = 0°. This 




array. Fluence maps for each IMRT and VMAT beam are measured with the 
MapCHECK® in absolute mode and compared against TPS generated fluences. A 
gamma analysis criteria of 3% / 3mm is routinely used with a 95% compliance rate 
required for plan approval. 
 
3.3 PHANTOMS 
3.3.1 Solid Water 
A Solid WaterTM (PTW RW3) phantom was used as build-up and backscatter 
material. By weight the PTW RW3 consists of carbon (67.22%), oxygen (19.84%), 
hydrogen (8.09%) and chlorine (0.13%). The solid water slabs have an effective 
atomic number of Z = 5.96 and have an electron density similar to water (1.012) 
rendering them water and tissue equivalent for photon beams up to 25 MV 
(Constanitinou 1982). 
 
3.3.2 Perspex Mini-Phantom 
A cylindrical Perspex mini-phantom was used for collimator scatter factor (Sc) 
measurements. The phantom was fabricated in-house, with a diameter of 4 cm and a 
length of 20 cm. A hole for the ionisation chamber was created in the phantom so 
that the ionisation chamber effective point of measurement (peff) was at a depth of 10 
cm.    
 
 






3.3.3 3D scanning water tank  
Dose profiles were measured using an ionisation chamber in the Blue Phantom 
scanning water tank (Scanditronix-Wellhöfer, Schwarzenbruck, Germany). Using 
this phantom, profiles could be obtained in the cross-plane and in-plane at different 
depths using an ionisation chamber or diode. 
 
 
Figure 3.3.3.1: Scanditronix-Welhoffer Blue Phantom 3D scanning water tank used 
for measurement of beam profiles. 
 
3.4 TREATMENT PLANNING SYSTEMS 
Treatment planning systems (TPS) were used in this research to create QA plans for 
IMRT and VMAT patient treatments for verification with EPID measurements. The 
TPS was used to generate a QA plan on a water phantom at a reference depth (choice 
based on output factor measurements). Each QA beam was calculated on the 
phantom and a two-dimensional dose fluence map was exported at the reference 







Figure 3.4.1: Patient  IMRT plan (left) with beams calculated on a water phantom 




The XiO® Treatment Planning System v4.64 (Elekta AB, Stockholm, Sweden) was 
used for the planning of conformal and IMRT fields in this project. XiO® is capable 
of 2D and 3D treatment plans including MLC-based IMRT, brachytherapy and 
proton therapy treatments. At Liverpool Cancer Care Centre and the Prince of Wales 
Hospital, this planning system is used for 3D conformal and IMRT treatment 
planning.  
 
Beam calculation methods of Fast Fourier Transformation (FFT) convolution, Pencil 
Beam, Multi-Grid Superposition and Fast Superposition can be employed by XiO® 
for calculation of absorbed dose in a patient or phantom. The chosen calculation 
method depends on the beam characteristics (photons or electrons) and the 
parameters of interest to the physicist (Mackie et al. 1997). Multi-Grid Superposition 
is the algorithm used at the Prince of Wales Hospital and Liverpool and Macarthur 
Cancer Therapy Centres for patient photon beam calculation. As a result, this method 
was used for beam calculation in this thesis.  
 
XiO® was used to generate a virtual water cube phantom with photon beams placed 




modulated fields were extracted at different depths (perpendicular to the beam axis) 
and exported for analysis.  
 
3.4.2 Monaco® 
Monaco® v 3.10 (Elekta AB, Stockholm, Sweden) was used for the calculation of 
patient IMRT plans onto a water phantom at reference depths dependent on the 
treatment beam energy. Monaco® is a dedicated IMRT and VMAT planning system 
that uses Monte Carlo algorithms for dose calculation and segmentation of IMRT 
patient plans.  
 
A Solid WaterTM phantom measuring 30 x 30 x 30 cm3 was imaged with the CT 
scanner and imported into Monaco® for IMRT QA calculations. A physical phantom 
was required due to an inability of Monaco® to calculate dose onto a virtual 
phantom. The phantom electron density was overridden to a relative electron density 
of 1.00 for all IMRT QA calculations, following department protocol. 
 
3.5 SOFTWARE ANALYSIS TOOLS 
3.5.1 Matlab® R2010a 
Matlab® R2010a (The Mathworks Inc, USA) was used as an image analysis tool in 
this thesis. The program is a comprehensive mathematical tool using matrices for 
data processing. A Graphical User Interface (GUI), array operations and matrix 
algebraic operations allow the program to be a useful tool in radiotherapy physics for 
solving imaging and dosimetry problems. 
 
Matlab® R2009a was used in this thesis to extract information and perform 






3.5.2 RIT v5.4 
RIT v5.4 (Radiological Imaging Technology Inc, Colorado Springs USA) is a 
commercial image analysis program specifically designed for use in radiotherapy. 
RIT v5.4 was used for the import and analysis of IMRT EPID images from the 
iViewGTTM and OptiVue1000STTM using vendor-specific image import functions. 
An IMRT routine is be used to evaluate the matching of measured and planned 
IMRT fluences in both absolute and relative modes. 
 
Figure 3.5.2.1: Gamma analysis result window for an IMRT field showing (from top 
left) absolute dose difference, calculated gamma map, pixel histogram and 3D 
absolute dose difference map (Obtained from RIT website). 
 
For the purposes of this research project, measured IMRT fluences with the EPID 
were imported into RIT v5.4 for comparison with planned fluences from XiO®. 
 
3.5.3 OmniPro I’mRT 
This software is a commercially based system designed to accompany the MatriXX 
I’mRT 2D ionisation chamber array. The OmniPro I’mRT (IBA-Dosimetry AB, 
Sweden) is an analysis tool for planned and measured doses, incorporating gamma 
analysis, dose difference, and DTA routines for comparison of data. The software 
was developed for use with the MatriXX array, radiochromic film and commercially 
available EPIDs (via DICOM import). 
 
Two-dimensional plan verification can be performed in OmniPro I’mRT between a 
measured data set and a planned dose data set. An illustration of the 2D plan 




displaying a measured fluence map (measured with the MatriXX array), the lower 
left window shows the planned dose fluence map for the radiation field. Analysis 
tools are shown in the right hand side of the workspace with dose profile comparison 
shown in the top pane and a 2D gamma analysis map shown in the lower pane. 
 
Figure 3.5.3.1: Screen shot of the IMRT comparison window on OmniPro I’mRT 
software with (clockwise from top-left) measured fluence, profile comparison 
between measured and planned doses, gamma analysis map, and planned fluence 
from XiO®. 
 
The OmniPro I’mRT software was used in this research project for comparison of 















4 METHODS  
 
All data acquired with the Elekta iViewGTTM and the Siemens OptiVue 1000STTM 
EPIDs were frame-averaged (image pixel values displayed in the image are the 
average pixel values for the whole radiation [over a multiple frame acquisition]), 
flood field corrected images. Frame–averaged images display the average EPID pixel 
value for an acquired number of frames for an irradiation. The integrated image was 
calculated from the frame-averaged image by multiplying the pixels by an inverse of 
the number of frames, the ‘FramePixelFactor’ which is a parameter included in the 
log file for Elekta acquired images and the number of frames found in the DICOM 
head of the Siemens acquired images. 
 
All EPID measurements were performed at 160 cm SSD for the Elekta iViewGTTM 
and at 145 cm SSD for the Siemens OptiVue 1000STTM.  
 
4.1 REPRODUCIBILITY 
The short term reproducibility of the Elekta iViewGTTM and the Siemens OptiVue 
1000STTM EPID panel were determined using repeat irradiations of the panel in a 
single session and evaluating the percentage standard deviation in average pixel 
value at the centre of the field.  
 
4.2 LINEARITY 
A linear detector response with delivered dose is a desirable characteristic for a 
radiotherapy dosimeter (Kahn 2010). The Elekta iViewGTTM and the Siemens 
OptiVue 1000STTM EPID panel response with delivered absorbed dose was 
calculated independently of the LINAC (eliminating start-up effects) by performing 
simultaneous measurements with an ionisation chamber. The linearity of the EPID 
panel, independent of the LINAC was calculated using equation 4.2 and was 
expressed as a percentage deviation from unity: 
 
ݕݐ݅ݎܽ݁݊݅ܮ = ቂ ோ(ா௉ூ஽,ெ௎)
ோ(ா௉ூ஽,ଵ଴଴ெ௎)
ቃ / ቂ ோ(௜௢௡ ௖௛௔௠௕௘௥ ,ெ௎)
ோ(௜௢௡ ௖௛௔௠௕௘௥,ଵ଴଴ெ௎)





Where R(EPID, MU) is the EPID response to a delivered number of monitor units 
(MU), R(EPID, 100MU) is the EPID response to a delivery of 100 MU, and similarly 
R(ion chamber, MU) is the ion chamber response to a delivered number of MU, and 
R(ion chamber, 100MU) is the ion chamber response to a delivery of 100 MU. 
 
4.2.1 EPID measurements 
A 10.4 x 10.4 cm2 field and a 10 x 10 cm2 were exposed onto the flat panel for the 
Elekta and Siemens LINACS respectively. Exposures of 1 – 200 MU were measured 
for 6 and 10MV with the mean pixel value in the central 10 x 10 pixels of the panel 
(corresponding to a 0.4 x 0.4 cm2 region of interest at the beam central axis) 
calculated for each exposure and normalised to the mean pixel value calculated for 
the 100 MU exposure. 
 
4.2.2 Ionisation chamber measurements 
Ion chamber measurements were performed at the same time as EPID acquisition to 
account for any ramp-up effects of the LINAC. The integrated charge (in nC) was 
collected for each exposure using a Farmer Type NE2571 (S/N: 2721) at a depth of 
10 cm in a RW3 solid water phantom at 100 cm SSD. The integrated charge for each 
exposure was normalised to the collected charge for the 100 MU exposure.  
 
The EPID linearity, independent of the LINAC, was calculated for each panel for 6 
and 10 MV beam energies by taking the ratio of the EPID normalised response with 
the ion chamber normalised response for each exposure.  
 
4.3 FIELD SIZE DEPENDENCE 
The absorbed dose in a material from a radiation beam changes as a function of 
irradiated field size. As the size/area of the radiation beam becomes larger, there is 
an increase in absorbed dose (in cGy per MU), on the beam central axis. This 




surface produced in the phantom material from the larger area/volume irradiated 
(Podgorsak 2005). 
 
4.3.1 EPID measurements 
To characterise the phantom scatter contribution from the EPID (due to non-water 
equivalent composition), field size response measurements were performed on each 
EPID for 6 and 10 MV. Integrated images were acquired for field sizes varying from 
2.4 x 2.4 cm2 up to 16 x 16 cm2 for the Elekta iViewGTTM and 2 x 2 cm2 to 22 x 22 
cm2 for the OptiVue1000STTM. The 16 x 16 cm2 maximum field size was used for 
the Elekta due to the maximum field size constraint of 16 x 21 cm. The average value 
in the central 10 x 10 pixel region for each field size was normalised to the average 
value in this region for the reference field size (10.4 x 10.4 cm2 for Elekta and 10 x 
10 cm2 for Siemens). 
 
4.3.2 Ion chamber measurements 
The integrated charge on the beam central axis (CAX) was collected using a small 
volume CC04 (S/N: 4524) ionisation chamber (IBA Dosimetry GmbH, Germany) in 
a Solid WaterTM RW3 phantom at 100 cm SSD for all EPID measured field sizes. 
The integrated charge for each field size was normalised to the charge collected for 
the 10.4 x 10.4 cm2 and 10 x 10 cm2 with the Elekta and Siemens LINACs 
respectively. Ionisation chamber measurements were performed at different depths in 
1 cm increments in the RW3 phantom to determine a reference depth in water (dref) 
at which the EPID scatter properties effectively match that of the ion chamber. Ion 
chamber measurements were performed multiple times both within and between 
sessions (n  9). 
 
 A quantitative comparison between the EPID and ionisation chamber measurements 
at each depth was provided by calculating the sum square of differences between 
normalised EPID data and normalised ionisation chamber responses at different 
depths in water. The depth of the ion chamber that returned the smallest difference 





4.3.3 Treatment Planning System verification 
To verify the accuracy of measured ionisation chamber field size responses, beams 
used for field size measurements from the Elekta and Siemens LINACs were created 
and placed onto a virtual water phantom in the XiO® TPS (Elekta AB, Sweden) at 
the previously determined dref . The virtual phantom dimensions were 40 x 40 x 40 
cm3 with each beam MU matching that used for measurements (100 MU per beam).  
 
The central axis dose (in cGy) was calculated by the TPS on the CAX at the 
reference depth for each field size and normalised to the dose for the 10.4 x 10.4 cm2 
and 10 x 10 cm2 reference field sizes. TPS-generated output factors were then plotted 
as a function of field size and compared to the ionisation chamber and EPID data.  
 
4.4 EPID SCATTER FACTOR MEASUREMENTS (Spe)  
To determine the contribution of the EPID panel scatter to the total scatter / field size 
response, the collimator scatter factor (Sc) for each LINAC was measured. The total 
scatter (Scp) response for the Elekta and Siemens EPIDs at 6 and 10MV was 
measured in Section 4.3. The Scp is a composite measurement of Collimator Scatter 
(Sc) and Phantom Scatter (Sp) for the same field size: 
 
)()()( FSSFSSFSS cpcp       (4.4.1) 
 
Collimator scatter includes photons scattered by all components of the LINAC head 
in the path of the treatment beam. Sc changes as a function of field size due to the 
amount of LINAC collimator and flattening filter ‘seen’ in the field.   
 
Phantom Scatter is the component of the measured dose at a point that results from 
scatter in the phantom material, this is directly related to the amount of phantom 
irradiated. This Sp value is independent of the collimator scatter contribution. 
Quantification of the phantom scatter component for the EPID (Spe) was determined 
by dividing the field size response of the panel (Scp,e)(FS) with the measured Sc(FS) 













pe        (4.4.2) 
 
By calculating the Spe for each panel it was possible to determine the internal scatter 
properties of the a-Si EPID and assess any effect on dosimetry. It has been well 
documented that due to the internal structure of the panel, the EPID will not be water 
equivalent due to the presence of silicon, phosphor, and metal layers (Deshpande et 
al. 2011). 
 
4.4.1 Collimator Scatter, Sc measurements 
A Perspex Mini-phantom was used for measurements as recommended by ESTRO 
Booklet 3 (1998). This mini-phantom was 4 cm in diameter and allowed a Farmer 
type NE 2571 (S/N: 2721) chamber to sit with the effective point of measurement 
(peff) at a depth of 10 cm from the surface. For Sc measurements to be accurate, the 
field size must fully encompass the mini-phantom (AAPM TG75). 
 
Measurements were performed at an SSD that matched the EPID SSD field size 
factor measurements. Field sizes were measured from 4 x 4 cm2 up to 16 x 16 cm2 
for the Elekta iViewGTTM (160 cm SSD) and 5 x 5 cm2 up to 22 x 22 cm2 for the 
Siemens OptiVue 1000STTM (145 cm SSD). Field sizes smaller than those stated 
could not be physically measured due to the dimensions of the mini-phantom; 
however, they could be extrapolated from the larger field size measurements.  
 
The charge collected with the ionisation chamber was normalised for each field size 
to the collected charge obtained for the 10.4 x 10.4 cm2 and 10 x 10 cm2 field sizes 
for the Elekta AxesseTM and Siemens OncorTM LINACs respectively. The normalised 
data was plotted as a function of field size, with a polynomial trend-line fitted. 
Extrapolation of the data to the smaller field sizes of 3 cm and 2 cm was performed 





4.5 EPID PIXEL-TO-DOSE CALIBRATION 
EPID images acquired were exported and displayed as a pixel value map for each 
EPID detector element across the entire panel area. For dosimetry purposes the pixel 
values in the EPID image were converted to dose using a Pixel to Dose Calibration 
Factor (CFEPID:Dose(x,y)). 
 
The calibration factor was calculated based on the average pixel value in the central 
10 x 10 pixels (0.4 x 0.4 cm2) region for a reference field size irradiated onto the 
panel, and the absorbed isocentric dose (in cGy) at the required reference depths for 
each energy and panel as found in Section 4.3. 
 
The reference field size used was 10.4 x 10.4 cm2 for the Elekta AxesseTM and 10 x 






yxCF drefDoseEPID      (4.5.1) 
 
EPID calibration factors were subsequently applied to all measured images for 
conversion of pixel values to dose (cGy). 
 
4.6 TREATMENT FIELD COMPARISONS 
To use the EPID for dosimetry of conformal and IMRT fields, the response of all 
pixels in the active detection area of the panel must be similar to those at an 
equivalent depth in water (determined by field size factor measurements in Section 
4.3).  
 
EPIDs have been documented to have a sharper penumbra, a larger response in the 
tail region due to scattering properties, and a flattened profile in the inter-umbral 
region due to the Flood Field correction compared to planning systems and other 
detectors (Greer 2005, Budgell et al. 2007, Gustaffson et al. 2009, Lee et al. 2009). 
Scattering properties in the EPID due to panel construction and a high resolution 
(0.4mm / pixel) contribute to the differences in dose profile between the EPIDs and 




generated dose profiles to examine the effect of the panel scatter properties on 
dosimetry for the verification of treatment fields.  
 
The XiO® v4.64 treatment planning system at the Prince of Wales Hospital was 
modelled using measured beam data from the time of commissioning of each of the 
LINACs. Measured data (profiles and PDDs) were collected using a small volume 
(CC04) ionisation chamber in a 3-D scanning water tank. The IMRT beam models 
for the Siemens and Elekta machines were used for calculations with a calculation 
grid resolution of 0.2 cm set. The calculation method used was Superposition 
(default method for all photon beam calculations in XiO®). The IMRT beam models 
have been previously verified against measurements for model validation. 
 
All treatment beams for comparison with EPID measured data were planned using 
XiO® on a uniform density water phantom with dimension 40 x 40 x 40 cm3. The 
beams planned with the TPS were exported at the reference depth determined for 
each machine and energy. 
 
4.6.1 Symmetric Open Field 
EPID measured dose profiles for field sizes of 10 x 10 cm2 (Siemens) and 10.4 x 
10.4 cm2 (Elekta) on the beam central axis in the A-B (cross-plane) direction for 6 
and 10 MV X-ray beams were compared with profiles generated by XiO® at dref and 
at dmax for each beam energy and LINAC.  
 
EPID integrated images for a 100MU exposure were normalised to a value of 1 at the 
central axis, with the cross-plane (central row [row index = 512]) and in-plane 
(central column [column index = 512]) pixels extracted for analysis. Dose profiles 
from XiO® were exported with the central cross-plane profiles extracted for 
comparison with the EPID. The percentage dose difference (%DD) in the useful 
beam (0.8 x Field size) was calculated between EPID and XiO® dose profiles.  The 
penumbral width (80% - 20%) and (90% - 10%) distances were also compared 





The penumbral widths for the EPID and XiO® profiles were calculated for each 
energy and depth. The EPID penumbra was hypothesised to be smaller / steeper than 
the penumbra calculated in water for the same radiation field due to the non-water 
equivalence of construction materials in the EPID. The TPS used both a conformal 
and an IMRT beam model for calculations. The conformal beam model was 
measured with a small volume ion chamber and the IMRT beam model was 
measured with a diode. Penumbral widths for ion chamber profiles were 
hypothesised to be larger than those measured with the EPID due to volume 
averaging effects. 
 
The low-dose region (tail of the profile) for the EPID and XiO® profiles were 
compared, with the maximum percentage difference between the profiles reported. 
 
4.6.2 Asymmetric Open Field 
The effect of an asymmetric field on the EPID output factor was measured using the 
Siemens OncorTM accelerator and OptiVue 1000STTM EPID.  
 
A rectangular field with the same equivalent square as a 10 x 10 cm field was 
measured with the EPID and compared to ionisation chamber results for that same 
field to ensure the output factor was equivalent for both dosimeters.  
 
A 14 x 8 cm2 field was measured using the EPID with the output factor calculated 
from normalisation of the central pixel region with that of the 10 x 10 cm2 field size. 
Measurements were repeated with a NE2751 Farmer ionisation chamber on the 
central axis in a solid water phantom. The ion chamber was positioned at the 
reference depth for the EPID as measured in Section 4.3.  
 
4.6.3 Picket Fence Field 
Picket fence fields were created in XiO® v4.64 for the Elekta AxesseTM and the 
Siemens OncorTM. The picket fence fields were planned as a static 20 x 20 cm2 field 
with different MLC leaves extended across the field. Each of the treated fields 




diagram of the leaf configurations are displayed in Figure 4.6.3.1 with dark blue 
areas representing regions of the treatment field underneath a projected MLC leaf, 
and lighter blue areas representing regions of the treatment field that are exposed to 
the beam and are between the MLC-shielded areas. 




101 1 leaf extended, with 1 leaf gap between 
102 1 leaf extended, with 2 leaf gap between 
104 1 leaf extended, with 4 leaf gap between 
201 2 leaf extended, with 1 leaf gap between 
202 2 leaf extended, with 2 leaf gap between 
204 2 leaf extended, with 4 leaf gap between 
301 3 leaf extended, with 1 leaf gap between 
302 2 leaf extended, with 2 leaf gap between 
304 3 leaf extended, with 4 leaf gap between 
 
 
Figure 4.6.3.1: Picket fence fields delivered to the Siemens OptiVue 1000STTM. (a) 
101, (b) 102 and (c) 103. 
 
Each treatment field was calculated using 6 MV and exported at the reference depth 
of 7 cm for the Elekta and Siemens EPIDs. 6 MV was used for comparison as at this 
energy as it provides a steeper penumbra than for 10 MV, hence differences in 




penumbra is wider. Gamma analysis was used for comparison of the treatment field 
with gamma criteria set from 1 cGy / 1mm up to 3 cGy/3mm. These fields provide a 
range of conditions to test the EPID dose response under varying scatter conditions. 
For example depending on the MLC pattern the regions underneath the extended 
MLC leaves are subject to differently weighted components of short and long range 
EPID scatter originating from the exposed detector regions, and MLC transmission. 
These experiments are designed to provide insight into the factors affecting 
agreement between EPID and dose in water under varying conditions of intensity 
modulations and to validate the choice of dref which was based on open field 
response.  
 
4.7  IMRT / VMAT DOSE VERIFICATION 
Patient IMRT and VMAT treatment fields were measured prior to the first fraction of 
treatment with the EPID and the MapCHECK® 2-D diode array and compared to 
TPS-generated planar dose fluences. Individual IMRT and VMAT treatment fields 
were measured with the EPID and MapCHECK® array for a variety of treatment 
areas using 6 and 10 MV photon beams. Each IMRT / VMAT beam was measured in 
QA mode with the gantry, collimator and couch angles set to zero degrees. VMAT 
beams were collapsed to a gantry angle of 0° for measurement and TPS comparison 
using the Elekta iViewGTTM EPID. Any dependence of the dose distribution on 
gantry angle will not be seen when collapsing the VMAT arc in these measurements. 
The dependence with gantry rotation may have a small effect on measured results, 
however the movement (sag) in the EPID panel with gantry rotation would likely 
mask these effects and create larger offsets in the measured images.  
 
4.7.1 IMRT / VMAT TPS Fluence map generation 
Dose fluences were generated for each IMRT patient field using XiO® v4.64 and 
Monaco® v3.1 planning systems (Elekta AB, Stockholm, Sweden). XiO® uses a 
Superposition algorithm for dose computation whereas Monaco® dose calculation is 





QA fields were created by transferring the patient plan to a virtual water phantom 
with dimensions 40 x 40 x 40 cm on XiO®, and onto a CT scan of a solid water 
phantom with dimensions of 30 x 30 x 30 cm for Monaco®. Due to software 
restrictions, Monaco® could not calculate dose on a virtual phantom.  
 
The planar dose maps were calculated using 100 cm source-to-detector distance 
(SDD) at depths corresponding to dref for EPID QA beams and at a depth of 3.0 cm 
for MapCHECK® QA beams. The planar dose maps for each IMRT beam was 
exported at these depths for EPID and MapCHECK® plans respectively. 
 
4.7.2 IMRT / VMAT Analysis 
IMRT field-by-field comparisons were performed using gamma analysis with 
clinical criteria of 3 cGy / 3 mm, and a 10% low dose threshold. A minimum of 95% 
of points passing the criteria was a requirement for plan approval. The IMRT suite in 
RIT v5.3 (Radiological Imaging Technology, Colorado Springs, USA) was used for 
Elekta iViewGTTM gamma analysis. OmniPro I’mRT (IBA Dosimetry GmbH, 
Schwarzenbruck, Germany) was used for Siemens OptiVue 1000STTM gamma 
analysis. Different programs were used for IMRT / VMAT comparisons due to 
compatibility issues with the different vendor image formats. 
 
Gamma analysis results, including the measured and planned dose planes for a head 
and neck field is shown in Figure 4.7.2.1. Regions of blue indicate areas in both 
fields that are within the gamma criteria of 3 cGy / 3 mm. 3 cGy / 3 mm criteria was  
used due to the limitation of the OmniPro software, where a percentage deviation is 
not readily calculated between the measured and planned profiles, but a cGy 
difference is reported and used for gamma analysis. Areas of red indicate areas 






Figure 4.7.2.1: IMRT field comparison between (a) an EPID measured IMRT 
fluence, and (b) a TPS-generated fluence for the IMRT field. The gamma analysis 
result for the field comparison is shown in (c). 
 
The gamma analysis result includes the number of pixels in the dose-map 




















Results for the methods in Chapter 4 of this thesis are presented below. 
 
5.1 REPRODUCIBILITY 
The short term reproducibility of the Elekta iViewGTTM and the Siemens 
OptiVue 1000STTM EPID panel were determined using repeat irradiations of 
the panel in a single session and evaluating the percentage standard deviation 
in average pixel value at the centre of the field. The percentage standard 
deviations for each panel response to 10 repeat irradiations are displayed in 
table 5.1.1. 
Table 5.1.1: EPID short-term reproducibility (percentage standard deviation in pixel 
value) for 10 repeat irradiations of the Elekta iViewGTTM and Siemens OptiVue 
1000STTM.  
 Percentage standard deviation (%) 
 6 MV 10 MV 
Elekta iViewGTTM 0.04 0.01 
Siemens OptiVue 1000STTM 0.04 0.04 
 
5.2 LINEARITY 
Linearity for the Elekta iViewGTTM and the Siemens OptiVue1000STTM were 
calculated independently of the LINAC for both 6 and 10 MV deliveries of 1 – 200 
MU by use of an independent ion chamber beneath the treatment beam.  
 
The Elekta iViewGTTM panel has user-defined settings for image acquisition. These 
settings include the number of frames acquired by the panel following the end of 
radiation (beam-off) called ‘PostBeamOffFrames’. This parameter was set as a 
default by Elekta for optimisation for patient imaging. The EPID collects three 
frames following radiation beam termination, increasing the number of frames 
acquired for all deliveries. Deliveries between 1 – 3 MU were seen to be largely 




amount of frames. The EPID linearity deviated from unity with smaller MU 
exposures due to the larger ratio of measurement frames to ‘PostBeamOffFrames’ 
with deviations up to± 7.8 % for 6 MV and ± 11.0 % for 10 MV. The 
‘PostBeamOffFrames’ parameter was subsequently set to zero with linearity 
exposures repeated. The linearity of the EPID improved with deviations of ± 4.1 % 
for 6 MV and to ± 3.5 % for 10 MV.  
 
Linearity measurements for the iViewGTTM for 6 and 10 MV using the 
‘PostBeamOffFrames’ parameter set to 3 (imaging default) and 0 are displayed in 
Figures 5.2.1 to 5.2.2. 
 
Figure 5.2.1: 6 MV linearity for Elekta iViewGTTM EPID with ‘PostBeamOffFrames’ 
setting set to 3 and 0, independent of the linear accelerator monitor chamber for 1- 





Figure 5.2.2: 10 MV linearity for Elekta iViewGTTM EPID with 
‘PostBeamOffFrames’ setting set to 3 and 0, independent of the linear accelerator 
monitor chamber for 1 - 200 MU delivery. 
 
Due to small MU deliveries for individual segments in an IMRT field, it was decided 
that the ‘PostBeamOffFrames’ parameter would be set to zero for all dosimetry 
image acquisitions with the EPID.  
The Siemens OptiVue 1000STTM has pre-set image acquisition settings that cannot 
be modified by the user (i.e. number of frames acquired following termination of 
radiation). These settings are optimised for patient imaging and required testing to 
assess the EPID response to delivered dose. 
 
Linearity measurements for the Siemens OptiVue1000STTM EPID for 6 and 10 MV 





Figure 5.2.3: 6 MV linearity for the Siemens Optivue1000STTM EPID independent of 
the linear accelerator monitor chamber for 1 - 200 MU delivery. 
 
Figure 5.2.4: 10 MV linearity for the Siemens Optivue1000STTM EPID independent 





All linearity plots have large error-bars for the low-MU deliveries. This is due to the 
instability of measurement of low MU irradiations and can also be attributed to 
incomplete charge collection from the panel due to frame acquisition. 
 
Figure 5.2.4 displays a dip in detector linearity around 2 and 3 MU. This was 
attributed to image lag and ghosting effects with small MU deliveries affecting the 
signal from the panel from a small MU delivery. 
 
The OptiVue 1000STTM was found to have a maximum deviation from unity of± 4.5 
% for 6MV and ± 4.6 % for 10 MV in the range of 1 – 200 MU.  
 
5.3 FIELD SIZE DEPENDENCE 
EPID and ionisation chamber response as a function of field size for the Elekta 
iViewGTTM and the Siemens OptiVue1000STTM are presented in Figures 5.3.1 to 
5.3.8. Qualitatively, the closest fit can be found between the EPID panel and a 
specific depth in water. Quantitative comparison between EPID and different depths 
in water was performed by computing the sum of square difference for each depth in 
water and the EPID. The lowest resulting sum square of difference between curves 
indicated the closest agreement between EPID field size response and ionisation 
chamber response, and indicated a reference depth in water (dref) that the EPID 





Figure 5.3.1: iViewGTTM output factor comparison to ionisation chamber output 
factors for different depths in water for a 6 MV beam. 
 
 
Figure 5.3.2: EPID, planning system and ionisation chamber comparison for d=7 





Elekta iViewGTTM 6MV field size responses are presented in Figures 5.3.1 and 5.3.2. 
A depth of 7 cm in water was determined as the dref for 6MV with a sum square of 
differences value of 0.001.  
 
Figure 5.3.3: iViewGTTM output factor comparison to ionisation chamber output 
factors for different depths in water for a 10 MV beam. 
 
Figure 5.3.4: EPID, planning system and ionisation chamber comparison for d=10 





A depth of 10 cm in water was determined as the dref for 10 MV with a sum square of 
differences value of 0.0002 calculated between measurements. 
 
Field size response comparison between the Siemens OptiVue1000STTM EPID and 
ionisation chamber measurements are presented in Figures 5.3.5 to 5.3.8. 
 
Figure 5.3.5: Optivue 1000STTM output factor comparison to ionisation chamber 





Figure 5.3.6: 6 MV EPID, planning system and ionisation chamber comparison for 
d=7cm using the Siemens Optivue 1000STTM EPID. 
 
A depth of 7 cm was calculated as the reference depth in water (dref) for the 
OptiVue1000STTM for 6 MV irradiations. The sum square of differences was 
calculated as 0.0006 between the EPID and the CC04 at 7 cm depth. 10 MV EPID 
and ionisation chamber comparisons are presented below for the OptiVue1000STTM, 






Figure 5.3.7: Optivue 1000STTM output factor comparison to ionisation chamber 
output factors for different depths in water for a 10 MV beam. 
Figure 
5.3.8: 10 MV EPID and ionisation chamber comparison for d=12 cm using the 
Siemens Optivue 1000STTM EPID. 
 
The sum square of differences was calculated for the EPID and CC04 ionisation 




The dref was found for each EPID at 6 and 10MV beam energies, and is presented in 
Table 5.2.1. The reference depths presented were subsequently used for open field 
and IMRT dosimetry comparisons, presented in Section 5.6 and 5.7. 
 
Table 5.3.1: Summary of reference depths in water for different vendor EPIDs for 6 





Photon Beam Energy 
(MV) 
Equivalent depth in 
water (cm) 
Equivalent depth in 
water (cm) 
6 7 7 
10 10 12 
 
5.4 EPID SCATTER FACTOR MEASUREMENTS (Spe) 
The Spe was calculated for each field size and energy using Equation 4.4.2. Results 
for the Elekta iViewGTTM and the Siemens OptiVue 1000STTM for 6 and 10 MV 
with comparison to the reference depth in water for the chosen beam energy are 






5.4.1: 6 MV comparison of Elekta iViewGTTM panel scatter as a function of field size 
with the phantom scatter in water at a depth of 7 cm and at depth of maximum 
absorbed dose. 
Figure 
5.4.2: 10 MV comparison of Elekta iViewGTTM panel scatter as a function of field 






Figure 5.4.3: 6 MV comparison of Siemens Optivue 1000STTM panel scatter as a 
function of field size with the phantom scatter in water at a depth of 7 cm and at 
depth of maximum absorbed dose. 
 
Figure 5.4.4: 10 MV comparison of Siemens Optivue 1000STTM panel scatter as a 





Differences between the measured Spe for each panel and the Sp for the reference 
depth in water for each energy were calculated. A maximum local percentage 
difference of 1.85% and 0.75% was calculated for the Elekta EPID, -0.85% and -
0.50% was calculated for the Siemens EPID for beam energies of 6 MV and 10 MV 
respectively. The marker for the Elekta iViewGTTM was reduced in size in Figures 
5.4.1 – 5.4.2 to enable visualisation of the error bars. The error bars in all EPID 
scatter measurement plots are attributed to the stability and reproducibility of each of 
the panels with irradiations of 100 MU. 
 
5.4.1 Collimator Scatter, Sc measurements 
The charge collected using the NE2571 ion chamber in the Perspex mini-phantom 
was normalised for each field size to the collected charge obtained for the 10.4 x 10.4 
cm2 and 10 x 10 cm2 field sizes for the Elekta AxesseTM and Siemens OncorTM 
LINACs respectively. The normalised data was plotted as a function of field size, 
with a polynomial trend-line fitted. Extrapolation of the data to the smaller field sizes 










Figure 5.4.1: Collimator scatter factor for Elekta Axesse as a function of field size 
foe 6 and 10 MV beam energies. The lines represent a 3rd order polynomial trend 
line fitted to the data. 
 
Figure 5.4.2: Collimator scatter factor for Siemens Oncor as a function of field size 
foe 6 and 10 MV beam energies. The lines represent a 3rd order polynomial trend 





Trend lines were extracted from the polynomial fit and were used to calculate the Sc 
for the smallest field sizes. The trend line equations are provided in table 5.4.1. 
 
Table 5.4.1: Trend line equations for 3rd order polynomial fit of collimator scatter 
data for the Elekta and Siemens linear accelerators. 
  Equation of 3rd order polynomial from Sc 
measurements 
Elekta Axesse 6 MV y = 0.920 + 0.146x - 0.001x2 + 0.00005x3 
 10 MV y = 0.928 + 0.117x - 0.001x2 + 0.00001x3 
Siemens Oncor 6 MV y = 0.887 + 0.018x - 0.001x2 + 0.00001x3 
 10 MV y = 0.901 + 0.016x - 0.001x2 + 0.00001x3 
  
5.5 EPID PIXEL-TO-DOSE CALIBRATION 
Calibration for the EPID panels was performed for 6 and 10 MV energies. 
Calibration factors were computed at each time of measurement using the central 10 
x 10 pixel values at the centre of the EPID field and the dose (in cGy) on the beam 
CAX at dref for each EPID and beam energy. The calibration factor was subsequently 
applied to all measured fields with the EPID. 
 
5.6 RADIATION FIELD COMPARISONS  
5.6.1 Symmetric Open Field 
Open fields were compared across the central axis of the measured and planned 
profiles. The profile from the central row of detectors was extracted from the EPID 
panels and compared against the central axis dose profile of the planned field. The 
dose profiles for Elekta and Siemens EPID images for 6 and 10 MV, compared with 





Figure 5.6.1.1: Dose profile comparisons between EPID and TPS-generated dose 
profiles at dmax and dref for (a) Elekta 6 MV, (b) Elekta 10 MV, (c) Siemens 6 MV and 
(d) Siemens 10 MV nominal beam energies. 
 
The percentage dose difference (%DD) was calculated between the EPID and TPS 
dose profile. The TPS dose profile was calculated at a depth of dmax and at the 
reference depth, dref for each energy. The %DD was calculated for the fields in the 
useful beam only which was the central 80% of the profile. This equated to a field 





Figure 5.6.1.2: 6 MV (a) and 10 MV (b) profile comparison and corresponding 
percentage dose difference plots (c) and (d) (b) for the Elekta iVireGTTM and XiO 






Figure 5.6.1.3: 6 MV (a) and 10 MV (b) profile comparison and corresponding 
percentage dose difference plots (c) and (d) (b) for the Siemens OptiVue 1000STTM 
and XiO planned profiles.  
 
Due to the flattening effect of the FF calibration, the characteristic horns on the dose 
profiles were removed when measured with the EPID. As a result the dose profiles 
were found to more closely match profiles at greater depths in water where the beam 
profile is flatter. Comparison of the useful beam dose between the EPID and water 
provided agreement across the field to within 4.5% for 6 MV profiles at the reference 
depth of 7 cm and agreement to within 2.1% across the profile for 10 MV at the 
different reference depths for both Elekta and Siemens LINACs. A difference in 
profile agreement between the EPID and water was observed between the 6 MV and 
10 MV energies, with the 10 MV EPID profiles having closer agreement with the 
profiles in water. This difference was attributed to the higher mean energy of the 
radiation beam causing increased lateral scattering range of the electrons in the panel 





The distance between the 80% - 20% and 90% - 10% points on the dose profile were 
used to calculate the penumbral width of the EPID and dose in water. The dose in 
water was calculated at a depth of maximum absorbed dose and at the reference 
depth for each energy. Penumbral regions for Elekta and Siemens EPID and TPS 
dose profiles are shown in figure 5.6.1.4 for 6 and 10 MV energies.  
 
Figure 5.6.1.4: Penumbral regions for EPID and TPS-generated dose profiles for (a) 
Elekta 6MV, (b) Elekta 10MV, (c) Siemens 6MV, and (d) Siemens 10MV dose 
profiles.  
The penumbral width (in mm) was calculated using the distance between the 80% 
and 20% points on the dose profile with calculated penumbral widths presented in 








Table 5.6.1.1: 80% – 20% and 90% - 10% penumbral width comparison for 6MV 
and 10 MV Elekta iViewGTTM profiles compared to profiles generated in a water 




80% - 20% 
Penumbral width 
(mm) 
90% - 10% 
Penumbral width 
(mm) 
EPID 6 MV 3.0 7.8 
XiO d=1.5 cm  6.0 9.5 
XiO d=7 cm  6.9 13.1 
EPID 10 MV 2.6 5.3 
XiO d=2.2 cm  6.6 10.4 
XiO d=10 cm  7.7 14.2 
 
Table 5.6.1.2: 80% – 20% and 90% - 10% penumbral width comparison for 6MV 
and 10 MV Siemens OptiVue 1000STTM profiles compared to profiles generated in a 




80% - 20% 
Penumbral width 
(mm) 
90% - 10% 
Penumbral width 
(mm) 
EPID 6 MV 4.2 8.0 
XiO d=1.5 cm  4.2 8.2 
XiO d=7 cm  6.0 11.1 
EPID 10 MV 2.6 6.0 
XiO d=2.2 cm  3.3 7.0 
XiO d=12 cm  8.0 11.0 
 
Penumbral widths measured by the EPID were sharper than those generated by the 
TPS at depths of dmax and at dref for both 6 and 10 MV energies. This difference is 
attributed to the shorter distances of electron lateral scatter in the EPID panel (due to 
construction materials) compared to the distance of electron lateral scatter in water. 
Differences in the penumbral widths measured with each EPID are related to 




characterise the panel response and contribute to the penumbral shape. Differences in 
TPS penumbral width depend on the individual LINAC and jaw / MLC design, as a 
result the widths (as modelled in the TPS) will be difference for the Elekta and 
Siemens LINACs. The effect of the penumbral width on modulated and IMRT 
measurements was monitored in Section 5.6.3 and 5.7. The low dose region of the 
dose profiles were compared between the EPID and XiO® for 6 and 10 MV 
energies, with the EPID profiles matching those at dref to within ± 4% in the region 
below 10%.  
 
Figure 5.6.1.5: Percentage difference calculated between the EPID and planning 
system profiles in the tail region for (a) Elekta – 6 MV, (b) Elekta – 10 MV, (c) 
Siemens - 6 MV, and (d) Siemens – 10 MV beams.  
 
5.6.2 Asymmetric Open Field 
The measured output factors for the 14 x 8 cm2 rectangular field were compared 
between ion chamber and the EPID. An output factor was calculated for the EPID as 




between the detectors. The difference in field shape was determined not to have a 
significant effect on the EPID sensitivity / dose response.  
5.6.3 Picket Fence Field 
Picket fence fields listed in Table 4.5.3.1 were planned using XiO® v4.64 and 
measured with EPID panels on the Elekta AxesseTM and Siemens OncorTM LINACs 
with a 6 MV beam.  
Gamma analysis was performed between measured and planned dose distributions 
for all modulated fields using 3 cGy / 3mm criteria with a 10 % low dose threshold.  
 
 
Figure 5.6.3.1: Comparison of 6 MV picket fence fields between EPID dose profiles 
measured with the Siemens OptiVue 1000ST (red) and XiO® calculated dose profiles 
at dref (7 cm) (green). Note that the number of leaves between the open regions of the 





With one leaf projected into the treatment field (as shown in (a) of Figure 5.6.3.1) the 
TPS calculated dose profile could not accurately model the modulated field. This was 
due to the contribution of the low-dose penumbra and tail from either side of the 
MLC leaf. With the field decreasing in modulation from the worst-case scenario (as 
seen in (b) and (c)), the dose profiles more closely match and provide better 
agreement with gamma analysis comparison. 
 
Gamma analysis was performed for all measured and planned field combinations 
using gamma criteria from 1 cGy / 1 mm up to 3 cGy / 3mm. Results for the 
iViewGTTM and OptiVue1000STTM are presented in Table5.6.3.1 and Table 5.6.3.2 
respectively. 
Table 5.6.3.1: 6 MV Elekta iViewGTTM gamma analysis results for Picket Fence 




















101 16.3 25.8 29.4 19.3 28.2 31.8 21.8 30.6 34.1 
102 30.2 24.3 30.2 18.5 27.6 33.8 21.4 31.0 37.5 
104 34.3 52.2 63.5 44.8 58.7 67.3 50.7 63.6 71.5 
201 19.2 39.4 45.7 22.9 39.4 50.2 26.2 42.1 53.2 
202 18.8 32.9 41.6 24.0 39.6 48.2 26.3 41.9 50.7 
204 35.6 56.7 68.0 47.4 66.3 76.6 55.7 72.3 80.4 
301 21.1 39.9 52.7 25.4 49.0 58.9 28.7 51.6 60.8 
302 19.0 35.4 47.6 24.9 44.1 56.0 27.1 46.3 58.3 











Table 5.6.3.2: 6 MV Siemens OptiVue 1000STTM gamma analysis results for Picket 




















101 26.3 44.0 51.1 39.0 59.5 66.9 49.7 71.0 77.1 
102 45.8 57.6 62.4 57.6 72.6 76.3 66.0 82.0 85.3 
104 57.0 68.4 74.5 70.4 84.3 84.3 77.0 88.0 90.2 
201 28.4 52.5 63.4 47.9 77.2 87.1 59.4 92.1 97.3 
202 28.4 52.5 63.4 47.9 77.1 87.5 65.3 93.1 98.8 
204 56.9 74.0 80.2 72.4 89.5 91.9 82.8 98.0 98.9 
301 28.4 50.1 61.1 51.6 79.5 88.6 61.9 94.6 97.5 
302 44.2 63.7 70.8 61.7 84.4 88.6 72.1 95.3 97.5 
304 62.5 77.6 81.8 75.1 90.1 92.2 82.8 97.1 98.2 
 
As the degree of modulation decreases from the highest modulation, with one leaf 
projected into the field between small open field regions, to an increase in distance 
between the projected leaves, the percentage of pixels passing the set gamma criteria 
also changes. The lowest pass rates for the Elekta iViewGTTM and the Siemens 
OptiVue 1000STTM were obtained for the field with alternating leaves projected into 
the treatment field with 1 leaf open between the leaves (16.3 % and 26.3 % 
respectively). The highest pass rates were obtained for the fields with a larger gap 
between the closed leaves.  
 
Differences were observed between the Elekta and the Siemens pass rates for the 
picket fence field. The Elekta panel had significantly lower pass rates for the fields 
with the highest degree of modulation. This was attributed to the differences in 
penumbra width for the EPID and the TPS (as reported in section 5.6.1). Differences 
between the pass rates for the picket fence between panels would not be clinically 
significant as IMRT and VMAT fields generally do not have this degree of 





5.7 IMRT / VMAT DOSE VERIFICATION 
Gamma analysis was performed on patient IMRT and VMAT fields measured with 
the EPID and the current department standard dose verification QA tool, the 
MapCHECK® diode array. Gamma criteria of 3 cGy / 3 mm, with a 10 % low dose 
threshold was used for all comparisons between measured and planned dose 
fluences. A 95 % pass rate (clinical acceptance rate) was used for each IMRT beam 
measured. 
 
The percentage of points passing the gamma criteria was calculated between the TPS 
(XiO® or Monaco®) and measurements obtained with the EPID and MapCHECK®. 
The average gamma result for the entire patient treatment (i.e. average pass rate for 
all IMRT beams measured for a patient) was calculated for both measurement 
techniques and compared. 
 
Individual treatment fields that differed by > 3 % in gamma pass rate between the 
two measurement techniques were subject to further investigation. Individual beams 
with gamma pass rates less than 95% were also investigated for their cause.  
 
Eight patients were compared for the Elekta AxesseTM LINAC. Of these eight, five 
were step-and-shoot IMRT and three were collapsed gantry VMAT deliveries. The 
iViewGTTM gamma results are displayed along-side the MapCHECK® results for 
each patient. Four patients were treated with 6 MV photons, and four were treated 












Table 5.7.1: Elekta iViewGTTM EPID and MapCHECK® diode array average plan 
gamma analysis result for step-and-shoot IMRT treatments on the Elekta AxesseTM 
linear accelerator. 
Percentage pixels passing gamma analysis per plan (%) 




1 Prostate 6 97.8 99.0 
2 Sacrum 6 95.6 98.2 
3 Paranasal Sinus 6 94.5 96.1 
4 Lung 10 96.5 99.9 
5 Prostate 10 97.7 99.1 
 
Table 5.7.2: Elekta iViewGTTM and MapCHECK® diode array average plan gamma 
analysis result for VMAT collapsed gantry QA fields on the Elekta AxesseTM linear 
accelerator. 
Percentage pixels passing gamma analysis per plan (%) 




6 Nasopharynx 6 97.2 99.6 
7 Head and neck 10 97.4 100.0 
8 Pancreas 10 98.0 99.7 
 
Gamma analysis results for IMRT pre-treatment QA were comparable to the results 
obtained when the fields were measured using the MapCHECK® diode array. A 
maximum difference of ± 2.6 % was found between the iViewGTTM and 
MapCHECK® for all step-and-shoot and VMAT fields. An average difference of 
±2.1 % was calculated for all treatments. All patient IMRT plans measured had a 
plan-average gamma analysis pass-rate greater than 95%.  
 
Three out of 35 EPID and one out of 35 MapCHECK® individual measured beams 
had pass rates <95%. One of these beams did not pass either measurement method 




position of the MLC leaves was verified with MLC QA and an investigation of the 
patient plan found no significant errors in the TPS or in the transfer of the plan to the 
record and verify system (LINAC delivery system). With no significant errors found 
and with the pass rate above90% for both measurement methods (EPID and 
MapCHECK), the beam was deemed to be acceptable for patient treatment. It must 
be noted that department protocol specified a minimum 90% pass rate, hence the 
beam passed clinical pass rates for plan acceptance. 
 
Ten patients were compared for the Siemens OncorTM LINAC. The OptiVue 
1000STTM gamma results are displayed along-side the MapCHECK® results for 
each patient. Seven patients were treated using 6 MV photons, and three patients 
were treated with 10 MV photons. 
Table 5.7.3: Siemens OptiVue 1000STTM and MapCHECK® diode array average 
plan gamma analysis result for IMRT treatments on the Siemens OncorTM linear 
accelerator. 
Percentage pixels passing gamma analysis per plan (%) 




9 Hypo-pharynx 6 99.3 98.4 
10 Head & Neck 6 98.5 100.0 
11 Base of Tongue 6 98.6 99.3 
12 Head & Neck 6 99.4 98.5 
13 Tonsil 6 99.4 99.2 
14 Nasopharynx 6 97.5 99.1 
15 SCC 6 97.4 98.8 
16 Prostate Bed 10 96.5 97.2 
17 Anus 10 97.6 99.5 
18 Anus 10 96.6 96.9 
 
Gamma analysis results for IMRT pre-treatment dose verification QA were 
comparable to the results obtained when the fields were measured using the 




the Optivue 1000STTM and MapCHECK® for all IMRT fields. An average 
difference of ±0.6 % was calculated for all treatments. All patient IMRT plans 
measured had a plan-average gamma analysis pass-rate greater than 95%.  
 
2 out of 57 EPID and 3 out of 57 MapCHECK® individual measured beams had pass 
rates <95%. One of these beams did not pass either measurement method and was 
further investigated for MLC positioning and plan calculation errors, again careful 
analysis of the MLC and the patient plan on the TPS was performed with no 









6 ANALYSIS OF ERRORS 
 
Uncertainties presented in this thesis are Type A uncertainties which are errors resulting 
from random fluctuations in measurement both in a measurement session and between 
measurement sessions. In this thesis Type A uncertainties include detector 
reproducibility, pixel age and function, variations in detector setup, panel positioning, 
and beam output. Type A uncertainties presented in the graphs in this thesis are based 
on 1SD of the measurements acquired for each setup. 
  
Type B uncertainties include systematic uncertainties present in the study that are 
related to the measurement setup. Type B uncertainties that must be considered when 
reviewing this thesis include variations in EPID panels of the same type due to 
manufacturing differences between the EPIDs used in this study and those outside of 
this study set (of the same detector-type). Type B uncertainties can be derived from 
previous experience and from published data (Bell 1999).  
 
An overall estimate of detector uncertainty can be obtained by adding Type A and Type 
B uncertainties in quadrature for all measurements, providing a total uncertainty which 
is approximately twice that of the Type A uncertainties. 
 
Methods to reduce uncertainties in this thesis were to ensure EPID panels were 
regularly serviced, with panel alignment, positioning and imaging QA performed on a 
quarterly and daily basis respectively. Variations in beam output due to daily 
fluctuations were minimised by measuring the absorbed dose at the reference depth and 
acquiring a calibration field with the EPID prior to all measurements. The absorbed 
dose and the reference image were used to calibrate all subsequent patient QA images to 
absolute dose. IMRT fields measured with the EPID and MapCHECK® in the same 








This thesis addresses the need for efficiency and accuracy in IMRT / VMAT dose 
verification QA in a limited-resource radiotherapy department by developing and 
evaluating a vendor-independent dose verification QA system using EPIDs. This work 
was based on a model for IMRT verification using Varian EPIDs presented by Lee et al. 
(2009). The method presented by Lee et al. (2009) was modified and extended upon to 
include equipment from different vendors, different treatment planning systems, and to 
include verification of VMAT. The development of the QA system included a 
comprehensive investigation of EPID dosimetric properties, determination of an 
equivalent depth in water where the EPID properties match that of water, EPID pixel-to-
dose calibration, and comparison of EPID measured vs. TPS calculated dose planes for 
conformal and IMRT / VMAT fields. 
 
EPID dosimetric properties examined in this thesis included short-term reproducibility, 
linearity, field size response, and EPID scatter. The short term reproducibility of both 
Elekta and Siemens EPIDs was found to be within 0.4%, which was consistent with 
0.5% found by Deshpande et al. (2011). EPID linearity has been reported for Elekta 
EPIDs by Budgell (2005), Winkler et al. (2006), and for Siemens EPIDs by Deshpande 
et al. (2011) with results indicating a loss of linearity of the panel response with low 
MU deliveries of up to 7% (Budgell et al. 2005). EPID linearity reported in chapter 5 of 
this thesis support results published by the above-mentioned authors, with panel 
linearity decreasing by up to 8% for low MU deliveries. Differences in panel 
construction, electronics, and read-out systems could contribute to different linearity 
values and as a result, EPID linearity must be measured and documented prior to 
implementation of a QA program. The field size response and subsequent generation of 
an EPID scatter factor was investigated by comparing the response of the EPID to field 
sizes from 2 x 2 cm2 up to 22 x 22 cm2, to the response of an ion chamber in water at 
different depths. EPID field size response and scatter factor has been measured by Greer 
and Popescu (2003), Winkler et al. (2006), Nijsten et al. (2007), Van Esch et al. (2007) 
and Deshpande et al. (2011) with a maximum difference of 9% found between ion 




et al. (2009) published that the non-water equivalence of the panel was due to the higher 
densities of the panel construction materials causing a change in response with energy 
spectrum. Consistent with Gustaffson et al. (2009), this thesis measured different 
phantom scatter properties between EPIDs and water at dmax. The steeper slope of the 
EPID response to a changing field size compared to dmax was attributed to differences in 
construction materials and the scatter properties of the panel. This indicated that the 
EPID approximates a water-equivalent detector at given reference depths. EPID scatter 
factors were compared with the phantom scatter in water at dref for both the Elekta 
iViewGT and the Siemens OptiVue 1000ST panels, with a maximum local percentage 
deviation of 1.85% calculated between EPID and water at the reference depth.  
 
A depth in water where the EPID scatter properties match that of water was investigated 
by Lee et al. (2009) for Varian EPIDs, with a depth of 5 cm in water found to be 
equivalent to the EPID response in a 6 MV beam. The Elekta and Siemens EPIDs were 
characterised in this thesis to have equivalent (reference) depths (dref) of 7 cm for 6MV 
photons for both panels. A depth of 10 cm for the Elekta and 12 cm for the Siemens 
EPID was determined as the EPID water equivalent depth for 10 MV photons. 
Absorbed dose at the reference depth in water in a 10 x 10 cm field size was then used 
to calibrate EPID pixel value to dose for extraction and analysis of absorbed dose 
fluence maps from the EPID.  
 
Comparison of EPID ‘dose’ images with TPS-generated fluence maps at dref for each 
panel was performed with conformal and IMRT fields. Conformal field comparison of 
open beams between the EPID and water provided agreement across the useful field 
(central 80% of the field) to within 4.5% for 6 MV profiles at the reference depth of 7 
cm and agreement to within 2.1% across the profile for 10 MV at the different reference 
depths. Penumbral widths for fields measured with the EPIDs were sharper than those 
generated by the TPS at both a depth of dmax, and at dref, with an average of 4.0 mm and 
2.0 mm for the Elekta and Siemens EPIDs respectively. The difference in penumbral 
width obtained between the EPID panels and the dose in water is due to scatter in the 
panel being different to that of water (due to the construction materials of the panel 
being non-water equivalent), and also due to the high resolution of the EPID (0.4 mm / 




Differences in penumbral width were also observed between the different EPID models 
which was attributed to the different construction and hence scattering properties of the 
panels. It was hypothesized that these discrepancies in penumbral width could have an 
effect on IMRT dosimetry measurements with the EPID, with test patterns of a highly-
modulated picket fence field performed to test this. Gamma analysis comparison of 
EPID-measured and TPS-planned picket fence fields were performed with higher pass 
rates obtained for comparison with the Siemens OptiVue 1000STTM than with the 
Elekta iViewGTM. This was attributed to the larger leaf width at the isocentre (5 mm) 
for the Siemens compared to 4 mm for the Elekta, and differences in penumbral widths 
in the TPS due to different MLC construction and shape (depending on the LINAC 
make / MLC model). Pass rates for the highly-modulated fields demonstrated that the 
effect of penumbral width plays a role in the pass rates calculated for EPID / TPS 
comparisons, however the extent of modulation was extreme in these cases and 
demonstrates a ‘worst-case’ scenario. A more clinically relevant degree of modulation 
such as the 204 and 304 fields provided closer agreement between EPID and TPS and as 
a result the EPID was used for measurement of IMRT and VMAT fields, comparing to 
TPS-generated fluences.  
 
IMRT and VMAT fields were measured with the EPID and MapCHECK® ion chamber 
array and compared to TPS-generated fluence maps. The Patient IMRT QA pass rates 
measured using the EPID for both Siemens and Elekta machines were comparable to the 
current department standard of IMRT dose verification QA using the MapCHECK® 2-
D diode array. As a result of the IMRT / VMAT detector comparison, the EPID was 
deemed to be a suitable tool for IMRT dose verification QA with the FF correction 
intact.   
 
This masters research thesis develops and provides a general model for per-patient pre-
treatment IMRT and VMAT dose verification QA using standard EPIDs that are 








In particular, the thesis presents:  
i. Characterisation of flood field corrected images for Elekta iViewGTTM and 
Siemens OptiVue 1000STTM EPID panels including panel reproducibility, 
linearity with dose, and EPID response with variation field size, to determine 
suitability of each EPID panel for dosimetry.  
ii. Determination of a reference depth in water (dref) for the Elekta iViewGTTM and 
the Siemens OptiVue 1000STTM, for 6 and 10 MV nominal beam energies. The 
reference depth is a depth in water where the scattering response of each EPID 
detector panel closely corresponds to the scatter properties of a reference 
dosimeter in water. The reference depth for each panel and energy were 
subsequently used for calibration of to generate dose profiles in a TPS for 
comparison EPID-measured and TPS-generated profiles for open and modulated 
fields.  
iii. A method to calibrate flood-field corrected EPID images from pixel values to 
dose, using the dose distribution in water at the reference depth for each panel 
and energy. The resultant calibrated images were compared to TPS-generated 
dose fluences at dref for both open and highly-modulated (picket fence) fields in 
the inter-umbral, penumbral and low-dose regions. Dose profile comparisons 
provided close agreement between the EPID panels and dref in these fields.  
v. Evaluation of the EPID dosimetry technique as a method for patient-specific 
dose verification QA of IMRT and VMAT plans using any combination of 
EPID, TPS, beam energy and delivery technique. The technique was tested on 
numerous clinical IMRT and VMAT patients and compared to current 
departmental QA methods using a commercial system. The method has been 
developed and used as a clinical IMRT / VMAT QA tool, and is routinely used 
as part of IMRT pre-treatment QA. 
 
The ability to use equipment that is already present in the radiotherapy department 
significantly reduces the financial burden of IMRT and VMAT implementation due to 
the need for an accurate dosimeter. The EPIDs are attached to the LINAC and as a 
result, the time taken for IMRT / VMAT dose verification QA measurements is 
minimised as there is no set-up of external QA devices in the treatment room and at the 




time on the treatment machine for physicists and may allow the IMRT fields to be 
delivered by the therapists in a ‘Fraction 0’ slot before the patient begins treatment. 
 
The results obtained for both the Siemens and Elekta LINACs for the gamma analysis 
of IMRT and VMAT fields using the EPID panels were comparable to the results 
obtained by Lee et al. (2009) using Varian LINACs and EPID panels. As there is 
currently no standard IMRT / VMAT dose verification QA technique across 
radiotherapy departments due to the different equipment and techniques used for 
verification of IMRT / VMAT, the model presented here could be used as a benchmark 
to compare IMRT delivery across multiple centres using multiple vendor planning 
























8 CONCLUSIONS AND FUTURE WORK  
 
The Elekta iViewGTTM and Siemens OptiVue 1000STTM EPID panels were investigated 
for their suitability for IMRT and VMAT QA using clinical flood-field corrected 
images. A simple vendor-independent EPID dosimetry procedure for use in pre-
treatment IMRT and VMAT dose verification QA was developed, evaluated and 
implemented.  
 
The EPID panels were deemed to be suitable for use as a radiotherapy dosimeter from 
reproducibility and linearity measurements performed for 6 and 10 MV beams. 
The panel energy response was characterised and evaluated with respect to water. A 
reference depth in water was found at which the EPID panel scattering properties 
matched that of water. The reference depth was found for each EPID panel for both 6 
and 10 MV and validated by measurement of the Spe. 
 
Following EPID pixel to dose calibration, the profile agreement between the EPID and 
planning system was examined for open symmetric and asymmetric fields as well as 
highly modulated fields. Results from comparisons indicated that while the EPID did 
not provide good agreement with dose in water in the penumbral regions nor in some 
highly modulated test patterns, the EPID demonstrated potential as a suitable dosimeter 
for clinical radiotherapy fields, and the suitability for use in IMRT and VMAT fields 
was subsequently investigated. 
 
Poor agreement in penumbral width between the EPID and the planning system for 
open fields has minimal effect in IMRT and VMAT treatments where individual 
treatment segments are delivered to produce a modulated field. In IMRT treatment field 
QA, the gamma analysis method is used whereby criteria of dose and distance to 
agreement (explained in section 2.4). The differences in penumbral width across the 
clinical fields were accounted for in the clinical DTA agreement criteria of 3mm, and 
therefore penumbral width differences between EPID and the TPS do not affect the 
gamma results for clinical IMRT fields. The highly-modulated picket fence test patterns 




VMAT treatment fields. The picket fence field was examined to analyse EPID response 
in the worst case scenario and determine any limitations of the model. The main 
observation found using the picket fence field was the limitation of the TPS to 
accurately model the small gaps between adjacent leaves as the modelled penumbra of 
each side of the field contributed to an increased dose in the shielded areas that was not 
present in the EPID measurement.   
 
Evaluation of IMRT and VMAT plan verification using the EPID was performed for 
clinical IMRT and VMAT patient plans, with gamma analysis performed between the 
EPID-measured and TPS-generated fluences. A variety of delivery techniques (sMLC 
and dMLC), energies (6 and 10 MV), planning systems (XiO® and Monaco®), and 
EPIDs (Elekta and Siemens) were used to validate the EPID QA procedure / system. 
Gamma analysis results were compared with gamma analysis results for fluences 
measured with the MapCHECK® diode array, which is the standard IMRT QA 
measurement device at the Prince of Wales Hospital. 
   
Using a gamma criteria of 3 cGy / 3mm for IMRT field comparison, all patient plans 
had an average gamma pass rate above 95%. EPID results agreed with the 
MapCHECK® diode array with an average difference of 1.3 % in gamma pass rates. 
 
Results from this study indicate that the EPID IMRT / VMAT dose verification QA 
procedure can be used as an accurate and reliable tool for per-patient pre-treatment dose 
verification QA across different platforms and delivery techniques. Further assessment 
is required to determine the procedures efficiency compared to the current standard 
methods, and to implement the system across multiple-departments with a still wider 
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